ArticlePDF AvailableLiterature Review

The Potential of the Mediterranean Diet to Improve Mitochondrial Function in Experimental Models of Obesity and Metabolic Syndrome

MDPI
Nutrients
Authors:

Abstract and Figures

The abnormal expansion of body fat paves the way for several metabolic abnormalities including overweight, obesity, and diabetes, which ultimately cluster under the umbrella of metabolic syndrome (MetS). Patients with MetS are at an increased risk of cardiovascular disease, morbidity, and mortality. The coexistence of distinct metabolic abnormalities is associated with the release of pro-inflammatory adipocytokines, as components of low-to-medium grade systemic inflammation and increased oxidative stress. Adopting healthy lifestyles, by using appropriate dietary regimens, contributes to the prevention and treatment of MetS. Metabolic abnormalities can influence the function and energetic capacity of mitochondria, as observed in many obesity-related cardio-metabolic disorders. There are preclinical studies both in cellular and animal models, as well as clinical studies, dealing with distinct nutrients of the Mediterranean diet (MD) and dysfunctional mitochondria in obesity and MetS. The term “Mitochondria nutrients” has been adopted in recent years, and it depicts the adequate nutrients to keep proper mitochondrial function. Different experimental models show that components of the MD, including polyphenols, plant-derived compounds, and polyunsaturated fatty acids, can improve mitochondrial metabolism, biogenesis, and antioxidant capacity. Such effects are valuable to counteract the mitochondrial dysfunction associated with obesity-related abnormalities and can represent the beneficial feature of polyphenols-enriched olive oil, vegetables, nuts, fish, and plant-based foods, as the main components of the MD. Thus, developing mitochondria-targeting nutrients and natural agents for MetS treatment and/or prevention is a logical strategy to decrease the burden of disease and medications at a later stage. In this comprehensive review, we discuss the effects of the MD and its bioactive components on improving mitochondrial structure and activity.
Content may be subject to copyright.
Citation: Khalil, M.; Shanmugam, H.;
Abdallah, H.; John Britto, J.S.;
Galerati, I.; Gómez-Ambrosi, J.;
Frühbeck, G.; Portincasa, P. The
Potential of the Mediterranean Diet
to Improve Mitochondrial Function
in Experimental Models of Obesity
and Metabolic Syndrome. Nutrients
2022,14, 3112. https://doi.org/
10.3390/nu14153112
Received: 5 June 2022
Accepted: 25 July 2022
Published: 28 July 2022
Publisher’s Note: MDPI stays neutral
with regard to jurisdictional claims in
published maps and institutional affil-
iations.
Copyright: © 2022 by the authors.
Licensee MDPI, Basel, Switzerland.
This article is an open access article
distributed under the terms and
conditions of the Creative Commons
Attribution (CC BY) license (https://
creativecommons.org/licenses/by/
4.0/).
nutrients
Review
The Potential of the Mediterranean Diet to Improve
Mitochondrial Function in Experimental Models of Obesity and
Metabolic Syndrome
Mohamad Khalil 1,2, Harshitha Shanmugam 1, Hala Abdallah 1, Jerlin Stephy John Britto 1, Ilaria Galerati 1,
Javier Gómez-Ambrosi 3,4,5 , Gema Frühbeck 3,4,5,6 and Piero Portincasa 1, *
1Clinica Medica “A. Murri”, Department of Biomedical Sciences & Human Oncology,
University of Bari Medical School, Piazza Giulio Cesare 11, 70124 Bari, Italy;
mohamad.khalil@uniba.it (M.K.); harshitha.shanmugam@uniba.it (H.S.); hala.abdallah@uniba.it (H.A.);
jerlin.johnbritto@uniba.it (J.S.J.B.); ilariagalerati@live.it (I.G.)
2Department of Soil, Plant and Food Sciences, University of Bari Aldo Moro, Via Amendola 165/a,
70126 Bari, Italy
3Metabolic Research Laboratory, Clínica Universidad de Navarra, 31008 Pamplona, Spain;
jagomez@unav.es (J.G.-A.); gfruhbeck@unav.es (G.F.)
4CIBER Fisiopatología de la Obesidad y Nutrición (CIBEROBN), ISCIII, 28029 Pamplona, Spain
5Obesity and Adipobiology Group, Instituto de Investigación Sanitaria de Navarra (IdiSNA),
31008 Pamplona, Spain
6Department of Endocrinology & Nutrition, Clínica Universidad de Navarra, 31008 Pamplona, Spain
*Correspondence: piero.portincasa@uniba.it; Tel.: +39-328-4687215
Abstract:
The abnormal expansion of body fat paves the way for several metabolic abnormalities
including overweight, obesity, and diabetes, which ultimately cluster under the umbrella of metabolic
syndrome (MetS). Patients with MetS are at an increased risk of cardiovascular disease, morbidity,
and mortality. The coexistence of distinct metabolic abnormalities is associated with the release of
pro-inflammatory adipocytokines, as components of low-to-medium grade systemic inflammation
and increased oxidative stress. Adopting healthy lifestyles, by using appropriate dietary regimens,
contributes to the prevention and treatment of MetS. Metabolic abnormalities can influence the
function and energetic capacity of mitochondria, as observed in many obesity-related cardio-metabolic
disorders. There are preclinical studies both in cellular and animal models, as well as clinical studies,
dealing with distinct nutrients of the Mediterranean diet (MD) and dysfunctional mitochondria in
obesity and MetS. The term Mitochondria nutrients has been adopted in recent years, and it depicts
the adequate nutrients to keep proper mitochondrial function. Different experimental models show
that components of the MD, including polyphenols, plant-derived compounds, and polyunsaturated
fatty acids, can improve mitochondrial metabolism, biogenesis, and antioxidant capacity. Such
effects are valuable to counteract the mitochondrial dysfunction associated with obesity-related
abnormalities and can represent the beneficial feature of polyphenols-enriched olive oil, vegetables,
nuts, fish, and plant-based foods, as the main components of the MD. Thus, developing mitochondria-
targeting nutrients and natural agents for MetS treatment and/or prevention is a logical strategy to
decrease the burden of disease and medications at a later stage. In this comprehensive review, we
discuss the effects of the MD and its bioactive components on improving mitochondrial structure
and activity.
Keywords:
obesity; mitochondria; Mediterranean diet; metabolic syndrome; plant-based foods;
polyphenols; polyunsaturated fatty acids
1. Introduction
Trends for obesity and metabolic syndrome (MetS) are dramatically increasing world-
wide and represent the “malnutrition” burden of the disease [
1
]. Obesity is characterized by
Nutrients 2022,14, 3112. https://doi.org/10.3390/nu14153112 https://www.mdpi.com/journal/nutrients
Nutrients 2022,14, 3112 2 of 31
excessive accumulation of adipose tissue combined with adipocytokine-mediated chronic
inflammation, mitochondrial dysfunction, and the inhibition of antioxidant defenses [
2
].
Obesity is typically linked to metabolic disorders such as hypertension, dyslipidemia, and
insulin resistance predisposing to type 2 diabetes (T2DM). Such metabolic abnormalities
tend to cluster within MetS [35].
Mitochondria contribute to the pathogenesis of obesity-related metabolic disorders.
Mitochondria are essential for cellular energy metabolism, as they generate adenosine
triphosphate (ATP) by oxidizing carbohydrates, lipids, and proteins [
6
8
]. Mitochondria
produce and eliminate the reactive oxygen species (ROS) [
9
]. The inability of mitochondria
to produce and maintain sufficient levels of ATP is known as “mitochondrial dysfunc-
tion”, which is the result of an imbalance in nutrient signal input, energy production, and
oxidative respiration [
8
,
10
]. Several studies suggest that an excessive intake of nutrients
influences mitochondrial function [
11
], and that obesity predisposes to mitochondrial
dysfunction [1215].
Basic, translational, clinical research, epidemiological studies, and society guidelines
find that the adoption of a healthy diet and lifestyle has beneficial preventive and therapeu-
tic effects on obesity and MetS. Among all dietary patterns, the typical Mediterranean Diet
(MD) is high in monounsaturated fatty acids, fiber, antioxidants, and glutathione [
16
,
17
].
Since adherence to the MD has been associated with a lower risk of obesity, T2DM, MetS,
coronary heart disease, and cardiovascular mortality [
18
23
], the MD is considered a
potential remedy for the prevention of obesity-related diseases [24].
In this scenario, the term mitochondrial nutrients refers to specific nutrients that can
preserve mitochondrial function. Cellular and animal models, as well as clinical studies,
have investigated the effects of components of the MD on dysfunctional mitochondria
in obesity and MetS. Thus, mitochondria represent a promising target for novel, natural
supplements or functional foods designed for the prevention and treatment of obesity-
related MetS. This is a reasonable strategy to decrease the impact of medications at a later
stage of the disease.
In this review, we will discuss the main features of obesity and MetS with respect to
mitochondrial function, as well as the effects of the MD and its bioactive components on
improving mitochondrial structure and activity [25].
2. Obesity
2.1. Definition
From a physiological perspective, body fat consists of brown and white adipose tissue.
By location, fat is found at the subcutaneous and visceral levels. According to the World
Health Organization (WHO), obesity is defined as the excessive accumulation of fat in the
body [
26
], as a result of sustained positive-energy balance where energy intake exceeds
energy expenditure [
27
]. Obesity is considered a disease of body-weight
regulation [28]
.
Expanded visceral adipocytes act as an endocrine organ, releasing adipocytokines ac-
tively involved in metabolic control, inflammation, and tissue repair [
29
,
30
], as well as
tumorigenesis [
31
,
32
]. Excessive visceral adipose tissue is associated with increased efflux
of long-chain fatty acids from adipocytes resulting in ectopic-fat deposition in the liver,
skeletal muscle, pancreas, and heart. These changes are associated with insulin resistance
and systemic gluco-lipidic toxicity. In a clinical context, obesity is associated with higher
cardiovascular risk, mortality, and morbidity [3336].
Obesity is typically assessed by the calculation of body mass index (BMI), expressed as
body weight in kilograms divided by the square of height in meters (kg/m
2
) [
37
]. Specific
reference standards exist for children by age and sex between the ages of 2 and 20 years. In
adults, BMI is independent of age and sex and is a surrogate marker of fat in the body [
36
].
In adults, BMI is classified into the following categories: underweight (<18.5 kg/m
2
), nor-
mal weight (18.5–24.9 kg/m
2
), overweight (25–29.9 kg/m
2
), and obese (
BMI 30 kg/m2
).
Obesity is further classified as class I (
BMI 30–34.9 kg/m2
), class II (
BMI 35–39.9 kg/m2
),
and class III obesity (BMI > 40 kg/m2), also known as severe obesity [38,39].
Nutrients 2022,14, 3112 3 of 31
Although simple to obtain, the classification based on BMI does not take into ac-
count several subtypes of obesity and the interaction between body composition and
cardiometabolic risk [
36
,
40
45
]. For example, the concept of metabolically healthy obesity
(MHO) describes a subtype of obese subjects with limited or no features of cardiometabolic
abnormalities. Conversely, some normal-weight subjects can display an elevated risk of
cardiometabolic disorders, termed “metabolically unhealthy normal weight” [
46
,
47
]. The
MHO phenotype displays a normal lipid and pro-inflammatory cytokine profile and insulin
sensitivity [
48
]. These patients have low visceral adiposity, high cardiorespiratory fitness,
and minimal or absent intima media thickness. Caution is required when classifying MHO
for several reasons. Longitudinal studies show that MHO can evolve into the metabolically
altered obesity (MAO) phenotype [
49
]. Nearly one-third of MHO patients, according to
fasting glycemia, exhibit impaired glucose tolerance or T2DM following an oral-glucose
tolerance test. Individuals with MHO and MAO have similar patterns of inflammatory
biomarkers such as C reactive protein, fibrinogen, uric acid, leukocyte count, serum amy-
loid A and hepatic enzymes, as well as adipokines such as adiponectin, resistin, leptin, and
angiotensin II. In addition, typical inflammatory gene expression in adipose tissue and the
liver shows comparable patterns in MHO and MAO individuals [
45
,
50
52
]. Notably, the
MHO phenotype is associated with accelerated age-related declines in functional ability
and jeopardizes the independence in older age [53].
Another phenotype of obesity is sarcopenic obesity (SO), a condition characterized
by the combination of low skeletal-muscle mass and decreased strength, i.e., “dynapenic”
abdominal obesity [
54
]. In the obesogenic environment, this condition is becoming more
important when considering the aging population [
55
,
56
]. A dangerous link exists between
obesity and sarcopenia, characterized by a mismatch between muscle mass and fat mass
with a negative impact on energy balance. This pathway, in turn, paves the way for weight
gain. In addition, obesity-associated chronic inflammation has a catabolic effect on muscle
mass, facilitating the loss of lean muscle combined with an increased risk for developing
metabolic alterations, cardiovascular disease (CVD), and mortality, at a much higher rate
than sarcopenia or obesity alone [5759].
2.2. Epidemiology of Overweight and Obesity
Overweight and obesity are chronic non-communicable diseases, and since 1980 their
prevalence has doubled worldwide. Over one-third of the population worldwide is now
classified as overweight or obese. By 2030, nearly 38% of the adult population will be
overweight and another 20% will be obese worldwide [
60
,
61
]. In 2015, evidence estimated
that obesity affected around 604 million adults and 108 million children worldwide [
62
]. In
2015, the prevalence of obesity had become higher among women than men, for all age
groups and at all socio-economic levels. From 1980 to 2015, the most pronounced increase
in the prevalence of obesity (11.1% to 38.3%) was observed in men aged 25 to 29 years in
low-to-middle income countries. Continuous increasing trends of severe types of obesity
is an area of concern. For instance, between the years 2007 and 2018, the age-adjusted
prevalence of class III obesity (BMI
40 kg/m
2
) increased from 5.7% to 9.2% [
63
,
64
]. As
will be discussed in the next sub-section, obesity is the key component of MetS [
65
67
], and
for this reason overweight and obese [
68
71
] populations are at elevated risk of several
metabolic disorders, including insulin resistance, dyslipidemia, hyperglycemia, CVD, and
many specific cancers [37,7276].
2.3. Metabolic Syndrome
MetS is characterized by specific criteria defined by the National Cholesterol Education
Program Adult Treatment Panel (ATP) III [
77
] and the International Diabetes Federation
(IDF) [
78
] (Table 1). The classification is based on the combination of at least three out
of the five following factors: visceral adiposity, increased serum triglycerides, low HDL
cholesterol, arterial hypertension, and elevated serum glucose (Figure 1).
Nutrients 2022,14, 3112 4 of 31
Nutrients 2022, 14, x FOR PEER REVIEW 4 of 33
2.3. Metabolic Syndrome
MetS is characterized by specific criteria defined by the National Cholesterol Educa-
tion Program Adult Treatment Panel (ATP) III [77] and the International Diabetes Feder-
ation (IDF) [78] (Table 1). The classification is based on the combination of at least three
out of the five following factors: visceral adiposity, increased serum triglycerides, low
HDL cholesterol, arterial hypertension, and elevated serum glucose (Figure 1).
Figure 1. Criteria for the definition of metabolic syndrome. WC: waist circumference, TG: triglycer-
ides, HDL: high-density lipoprotein, SBP: systolic blood pressure, DSP: diastolic blood pressure,
FPG: fasting plasma glucose.
The estimated prevalence of MetS according to IDF definition is higher than the prev-
alence of MetS, according to the ATP III definition [79]. MetS is gaining increasing epide-
miologic relevance [8082]. According to the Third National Health and Nutrition Exam-
ination Survey, the overall prevalence of MetS was 22%. In 2002 [83], another study re-
ported a worldwide prevalence of 10–30%, including children and adolescents [84]. An
age-dependent increase was observed from 6.7% to 43.5% to 42.0%, for ages 20 to 29, 60 to
69, and over 70 years, respectively. Ethnic differences exist, with the highest age-adjusted
prevalence among Mexican Americans (31.9%). Among Black Americans and Mexican
Americans, the prevalence of MetS was 57% and 26%, which was higher in women than
men.
Figure 1.
Criteria for the definition of metabolic syndrome. WC: waist circumference, TG: triglyc-
erides, HDL: high-density lipoprotein, SBP: systolic blood pressure, DSP: diastolic blood pressure,
FPG: fasting plasma glucose.
The estimated prevalence of MetS according to IDF definition is higher than the
prevalence of MetS, according to the ATP III definition [
79
]. MetS is gaining increasing
epidemiologic relevance [
80
82
]. According to the Third National Health and Nutrition
Examination Survey, the overall prevalence of MetS was 22%. In 2002 [
83
], another study
reported a worldwide prevalence of 10–30%, including children and adolescents [
84
]. An
age-dependent increase was observed from 6.7% to 43.5% to 42.0%, for ages 20 to 29,
60 to 69, and over 70 years, respectively. Ethnic differences exist, with the highest age-
adjusted prevalence among Mexican Americans (31.9%). Among Black Americans and
Mexican Americans, the prevalence of MetS was 57% and 26%, which was higher in women
than men.
Table 1. Criteria for the definition of metabolic syndrome.
National Cholesterol Education Program ATP III [77]International Diabetes Federation
(IDF) [78]
Any three of the following five abnormalities: Central obesity plus any two of the following four factors:
Obesity Abdominal obesity is defined as a waist circumference 102 cm in men
and 88 cm in females
Increased waist circumference, with ethnic-specific
waist-circumference cut-off points *
Triglycerides Serum triglycerides 1.7 mmol/L or drug treatment for
elevated triglycerides
Triglycerides 1.7 mmol/L or drug treatment for
elevated triglycerides
HDL cholesterol Serum high-density lipoprotein (HDL) cholesterol <1 mmol/L in males
and <1.3 mmol/L in females or drug treatment for low HDL cholesterol
HDL cholesterol < 1.03 mmol/L in men or <1.29 mmol/L in
females or drug treatment for low HDL cholesterol
Hypertension Systolic blood pressure 130mm Hg, diastolic blood pressure 85 mm
Hg or drug treatment for elevated blood pressure
Systolic blood pressure 130 mm Hg, diastolic blood
pressure 85 mm Hg, or treatment for hypertension
Glucose Fasting plasma glucose (FPG) 100 mg/dL (5.6 mmol/L) or drug
treatment for elevated blood glucose
FPG 100 mg/dL (5.6 mmol/L) or previously diagnosed
type 2 diabetes; an oral glucose tolerance test is recommended
for patients with an elevated FPG, but it is not required
* Europid populations: males
94 cm; females
80 cm; South Asian populations, Chinese populations, and
Japanese populations: males
90 cm; females
80 cm; South and Central American populations: use South
Asian recommendations until more specific data are available; Sub-Saharan African, Eastern Mediterranean, and
Middle Eastern populations: use European data until more specific data are available [85].
Nutrients 2022,14, 3112 5 of 31
The cause of MetS is complex, and the major etiological components are considered to
be genetic, environmental, and lifestyle factors [67,8690].
Defective cell metabolism is an important contributing factor for MetS because of
an imbalance between nutrient intake and utilization for energy. Diminished fatty-acid
oxidation accelerates elevation in the intracellular aggregation of fatty acyl-CoAs as well as
other fat-derived molecules in the liver, skeletal muscle, and adipose tissue [
86
]. Patients
with MetS display early evidence of insulin resistance, with initial elevated serum-insulin
levels. At a later stage, and if not properly treated, this condition can progress to T2DM.
Associated conditions with MetS include cholesterol cholelithiasis and liver steatosis [
91
,
92
].
Cholesterol cholelithiasis originates from excessive secretion of hepatic cholesterol, which
makes bile supersaturated and prone to the precipitation and aggregation of monohydrate
cholesterol crystals, which grow into stones in the gallbladder [
93
97
]. The second condition
is non-alcoholic fatty liver disease (NAFLD), recently renamed metabolic dysfunction-
associated fatty liver disease (MAFLD) [
98
]. NAFLD/MAFLD originates from excessive
intrahepatic influx of circulating long-chain fatty acids, with accumulation of triglycerides
and toxic metabolites in the hepatocytes [69,99103].
In this metabolically unhealthy scenario, several determining metabolic pathways con-
verge in mitochondria, suggesting that obesity and MetS are associated with mitochondrial
dysfunction, and pointing to a type of metabolic mitochondrial disease [
68
,
69
,
102
,
104
,
105
].
In MetS, mitochondrial dysfunction has been identified in various target organs such as
the liver, heart, and skeletal muscle, as well as in tissue and cells such as adipocyte and
pancreatic islet beta cells [
106
]. Nevertheless, it is still unclear if mitochondrial dysfunction
is the primary cause or a secondary effect of MetS.
3. Mitochondria, Bioenergetics, Obesity, and MetS
3.1. Mitochondria and Bioenergetics
Mitochondria are small intracellular organelles with a double membrane structure,
i.e., the outer mitochondrial membrane (OMM) and inner mitochondrial membrane (IMM),
separated by the intermembranous space [
102
,
107
]. Mitochondria are the “powerhouse of
the cell” and the main sites for ATP production. Using beta-oxidation and the citric acid
cycle, mitochondria oxidize the long-chain fatty acids and glucose derived from foods [
108
].
Starting from chemical bonds in foods, high-energy electrons are produced and captured by
nicotinamide adenine dinucleotide (NAD) and flavin adenine dinucleotide (FAD) and later
reduced to NADH and FADH
2
[
109
]. High-energy electrons are donated to the electron
transport chain (ETC) by NADH and FADH
2
. The ETC is based in IMM and consists of five
complexes [
110
,
111
]. NADH donates electrons to complex I, FADH
2
donates electrons to
complex II, and both complexes I and II donate electrons to coenzyme Q (CoQ) [
68
71
,
112
].
CoQ is freely diffusible through IMM and provides electrons to complex III and
reduces cytochrome c. Complex IV oxidizes cytochrome c and transfers electrons to oxygen
to produce water. The movement of electrons along the transport chain releases free energy
that is used to pump protons at complex I, III, and IV from the mitochondrial matrix into
the intermembranous space, generating a proton gradient [
110
,
113
]. Protons diffuse along
its concentration gradient at complex V, releasing energy that is used to create ATP from
ADP [
114
]. This process is also known as oxidative phosphorylation (OXPHOS) [
115
]. Over
90% of the total cellular ATP is generated in the mitochondria, and this pathway is at the
center of energy metabolism [102] and can become dysfunctional in MetS.
3.2. Mitochondria and Reactive Oxygen Species (ROS)
Mitochondria play a key role in ATP production but are also an important source of
physiological levels of intracellular ROS [
116
]. As electrons pass through the ETC, a small
fraction escape and prematurely react with molecular oxygen, generating superoxide radi-
cals that are spontaneously or enzymatically converted into hydrogen
peroxide [117,118]
.
Furthermore, by undergoing the Fenton reaction, hydrogen peroxide can produce hydroxyl
radicals that are harmful and highly reactive molecules [
119
,
120
], which can cause cell
Nutrients 2022,14, 3112 6 of 31
death by damaging membranes, proteins, DNA, and enzymes [
121
]. Mitochondria host a
very well-structured antioxidant mechanism that includes the homotetrameric Manganese
(Mn) superoxide dismutase (MnSOD = SOD2), which in mammals is found solely in the
mitochondria at the level of the matrix and intermembrane space [
122
]. SOD2 converts su-
peroxide radicals to hydrogen peroxide and molecular oxygen. In the presence of reduced
glutathione, hydrogen peroxide is converted to water by the enzyme glutathione perox-
idase, minimizing the production of hydroxyl radical [
123
]. This process is very highly
efficient and scavenges most of the ROS produced locally in mitochondria. Mitochondria
also play a key role in ROS scavenging from other cellular sources, and mitochondrial
dysregulation can lead to unrestricted ROS generation and cell injury [
124
127
]. Excessive
production of ROS exceeding cellular antioxidant defense causes cellular macromolecule
damage and affects cellular viability and functions, a process called oxidative stress [
128
].
Oxidative stress is widely recognized as one of the deciding mechanisms for several disease
processes including MetS [
129
]. An increase in hydrogen peroxide and superoxide in
cells modifies intracellular signaling and can lead to metabolic reprogramming resulting
in increased fat synthesis and storage [
130
]. Therefore, increased ROS production with
subsequent oxidative stress may add to the pathogenesis of MetS.
3.3. Mitochondrial Biogenesis
Mitochondria have their own DNA, which encodes for only 22 mitochondrial t-RNA
and some components of the ETC [
131
]. The key master regulator and transcriptional
activator of mitochondrial biogenesis is the peroxisome proliferator–activated receptor
gamma coactivator-1
α
(PGC-1
α
) [
132
,
133
]. Furthermore, by activating various other
transcription factors, PGC-1
α
stimulates the process of mitochondrial biogenesis involved
in nuclear and mitochondrial gene expression [
134
]. The induction of mitochondrial
transcription factor A (TFAM) is led by the activation of nuclear respiratory factors 1 and 2
(NRF-1 and NRF-2), transcription factors, and estrogen-related receptors (ERRs) [
135
,
136
].
TFAM interacts directly with mitochondrial transcription factor B2 (TFB2M) along with the
mitochondrial genome, to induce mitochondrial gene transcription [
137
]. Mitochondrial
biogenesis is the physiological response to increased energy demand by AMP-activated
kinase (AMPK) to monitor cellular-energy status [
138
]. The AMPK system responds
to rises in the AMP:ATP ratio rather than to rises in AMP alone [
139
]. Increased AMP
mediated by AMPK and elevated NAD+ mediated by Sirtuin-1 pathways can cause PGC1
α
activation, which in turn decreases cellular oxidative stress by enhancing the expression
of mitochondrial antioxidant enzymes [
140
,
141
]. Hence, PGC1
α
has become a significant
therapeutic target for MetS [
142
146
]. Therapeutic approaches focusing on enhanced
mitochondrial biogenesis not only improve mitochondrial efficacy for substrate handling
but also decrease oxidative stress, providing multifactorial benefits [147149].
3.4. Mitochondrial Dysfunction in Obesity
The pathological expansion of body fat is associated with a chronic status of low-
to-medium grade inflammation, oxidative stress, and insulin resistance [
30
,
150
]. These
changes can be paralleled by dysregulation of mitochondrial function and biogenesis.
An excessive intake of nutrients, especially lipids and carbohydrates, can promote
mitochondrial dysfunction. Due to high-calorie intakes, the metabolism is shifted towards
the lipid reservoir, reduced mitochondrial function, and biogenesis, with subsequent pro-
duction of ROS and the progression of insulin resistance in the liver, muscle, and adipose
tissue [
8
]. By using hypertrophic adipocytes as an experimental
in vitro
cellular model of
obesity, we showed that lipid accumulation and oxidative stress are associated with im-
paired mitochondrial oxygen consumption and alteration of mitochondrial complexes [
105
].
In addition, lipolysis, adipogenesis, and adipocyte-derived adiponectin production were
abnormal in adipocytes along with deranged insulin sensitivity [
151
]. In skeletal muscle
obtained from rodents and humans, the obesity-induced status by a high-fat diet increased
the H
2
O
2
-emitting potential of mitochondria, shifting the cellular-redox environment to a
Nutrients 2022,14, 3112 7 of 31
more oxidized state and decreasing the redox-buffering capacity. These events occurred
in the absence of any changes in mitochondrial respiratory function. Notably, the authors
reported that attenuating mitochondrial H
2
O
2
emission by either treating rats with an
antioxidant-targeting mitochondrial or by genetically engineering the overexpression of
catalase in mitochondria of muscle cells in mice, preserved insulin sensitivity despite the
high-fat diet [152].
The relationship between mitochondrial dysfunction and obesity has been also inves-
tigated in animal models. More precisely, db/db mice and mice on a high-fat diet under
diabetes/obesity conditions displayed a reduction in mitochondrial ATP production and
alterations of mitochondrial structure [
153
]. In high-fat-diet, obese mice, mitochondrial
dysfunction also occurs in the liver, mediated by a decrease in the expression of carnitine
palmitoyltransferase-1 (CPT-1), citrate synthase, nuclear respiratory factor-1 (NRF-1), and
mitochondrial transcription factor A (TFAM) [154].
The role of obesity in mitochondrial dysfunction has been also investigated in
humans [155]
.
Adipocytes collected from omental and/or abdominal subcutaneous adipose samples of
obese patients showed a reduction in mitochondrial oxygen-consumption rates and citrate
synthase activity, compared to non-obese subjects [
13
]. Mitochondrial biogenesis, mito-
chondrial oxidative phosphorylation, and oxidative metabolic pathways in subcutaneous
adipose tissue are downregulated in obese subjects, when compared to lean subjects [
15
].
These effects were accompanied by a reduction in the amount of mtDNA and the mtDNA-
dependent translation system. At the molecular level, obese subjects showed reduced
peroxisome proliferator–activated receptor-
α
(PGC1-
α
) expression, as a marker of altered
mitochondrial biogenesis [156].
3.5. Mitochondrial Dysfunction in MetS
Mitochondrial dysfunction is a cardinal hallmark of MetS [
69
]. In the liver, mito-
chondria are involved in the metabolic pathways of lipids, proteins, carbohydrates, and
xenobiotics [157,158]
. Mitochondrial dysfunction is documented in NAFLD/MAFLD, the
most common chronic liver disease [
69
,
102
,
104
,
105
,
159
]. In the early stages of NAFLD/MAFLD
the increased intrahepatic influx of circulating FFAs causes early mitochondrial biogenesis
mediated by the activation of PGC1-
α
and increased
β
-oxidation rates [
160
,
161
]. The high
rate of FFA oxidation and ATP synthesis cause the uncontrolled increase in ROS level
and changes in mitochondrial structure/function such as swelling, alteration in the mito-
chondrial electron transporter chain, mitochondrial DNA (mtDNA) damage, and sirtuin
alteration. Despite the endogenous mitochondrial antioxidant system works to counteract
the oxidative stress, the mitochondrial dysfunction occurs with imbalance between ROS
production and mitochondrial defense mechanisms [162].
As NAFLD/MAFLD progresses, the increased levels of ROS severely impairs mtDNA
function [
39
] and mitochondrial ATP synthesis promoting further hepatic
dysfunction [163166]
,
and inflammation [
167
170
]. At the structural level, the mitochondrial electron transfer
chain seems to be altered as consequence of the excessive accumulation of toxic lipids
and mitochondrial ROS (mtROS) with a direct impact on the permeability of the inner
mitochondrial membrane and increased oxidative damage [
171
]. At the molecular level,
mitochondrial cytochrome P450 2E1 (CYP2E1), which is responsible for long-chain fatty
acid metabolism, is directly involved in mitochondrial ROS production, and is considered
a fundamental player in NAFLD/MAFLD pathophysiology [
172
]. Indeed, experimental
studies on non-alcoholic steatohepatitis (NASH) in animal models and in humans, showed
an increased activity of CYP2E1 [
173
,
174
]. Besides, mitochondrial enzymatic oxidative
defense mechanisms resulted also impaired in NAFLD and NASH with progressive mito-
chondrial dysfunction. Furthermore, alteration of the expression PGC-1
α
are associated
with NAFLD pathogenesis and to NASH-hepatocellular carcinoma progression [175].
The relationship between insulin resistance and mitochondrial dysfunction is not
fully understood. Increased production of mtROS has been associated with a high glucose
intake and FFAs accumulation, the two principal factors of insulin resistance. Despite
Nutrients 2022,14, 3112 8 of 31
the established role of genetic and environmental factors associated with T2DM patho-
physiology, different metabolic abnormalities are directly implicated in the etiology of
T2DM.With ongoing insulin resistance and pancreatic
β
-cell dysfunction, mitochondrial
dysfunction has been indicated as a principal contributor. The reduction in insulin sen-
sitivity in adipocytes, hepatocytes, and skeletal muscles is related to other complications
such as the increased production of ROS and an accumulation of FFAs, both of which
are associated with mitochondrial dysfunction and impaired mitochondrial biogenesis in
diabetic patients [176178].
In overweight/obesity and MetS, high fat and carbohydrate intake leads to lipid depo-
sition resulting in the expansion of visceral adipocytes and an excessive influx of circulating
FFAs [
36
]. The involvement of metabolic abnormalities (e.g., visceral fat accumulation,
insulin resistance, and inflammation) in obesity is closely related to mitochondrial dysfunc-
tion and vice versa [
179
,
180
]. In experimental animal models, the accumulation of fat and
formation of adipose tissue in obesity are correlated with increased ROS production. In
addition, obese mice showed a mitochondrial dysfunction phenotype indicated by increas-
ing NADPH oxidase expression and reducing antioxidative enzymes [
181
,
182
]. In obese
mice, Choo et al. [
183
] showed that the number of mitochondria and mtDNA are reduced
in adipocytes. Dysfunctional fatty acid oxidation and mitochondrial respiration were also
observed. Similarly, mitochondrial biogenesis was strongly suppressed in the adipocytes of
obese mice. Mitochondrial ATP production occurred with molecular (PGC-1
α
/
β
, estrogen-
related receptor alpha, and PPAR-
α
) and structural (outer and inner membrane translocases
and mitochondrial ribosomal proteins) alteration in adipose tissue [153].
Two main mechanisms of damage include ATP depletion and excessive ROS produc-
tion. Mitochondrial dysfunction in association with adipose tissue dysfunction, plays a
role in aging [
184
,
185
]. Thus, based on the pivotal role of mitochondria in the pathogenesis
of MetS, targeting mitochondrial dysfunction for the treatment of MetS is of great inter-
est. There is growing evidence from animal and human models that sheds light on the
beneficial effects of nutrition-based intervention targeting mitochondria in MetS. Diets
rich in polyphenols such as the MD could represent one of the healthiest approaches for
nutritional intervention for the prevention and/or treatment of MetS.
4. Diet, Features, and Effects
The proper maintenance of metabolic homeostasis is closely related to food and
nutrient intake. Both epidemiological and clinical evidence suggests that dietary patterns
are closely related to the incidence and complications of MetS [
186
,
187
]. The Western diet,
characterized by the high intake of refined grains, red meat, and fried foods, is associated
with a greater risk of developing one or more components of MetS [
188
]. Low-fat diets
such as the vegan diet, characterized by the absence of all animal-based products, if well-
balanced, can promote health and reduce the risk of MetS [
189
]. A well-balanced diet, such
as the MD is associated with lower incidence and risk of MetS (Table 2).
Table 2. Principal features of Western diet, Vegan diet, and Mediterranean diet.
Western Diet Vegan Diet Mediterranean Diet
Characteristics High fat and sugar
High vegetable Low meat
Low fat High vegetable and olive oil
No meat High plant-based foods
Main components
Red meat Fiber Fiber
(Saturated fat and cholesterol) Grain Antioxidants
Refined grains Cereals Unsaturated fats
Fructose beverage Whole grain
Health consequences
Obesity
Healthy (if balanced)
Deficiency of essential macro and
micronutrients (if unbalanced)
Healthy
Insulin resistance
NAFLD
Diabetes
CVD
Nutrients 2022,14, 3112 9 of 31
Table 2. Cont.
Western Diet Vegan Diet Mediterranean Diet
Mechanisms
Adipose tissue
Circulating FFAs
Hepatic lipid accumulation
Triglycerides
Cholesterol
Fasting glucose
De novo lipogenesis
VLDL
ER stress
Lysosomal permeabilization
Insulin sensitivity
Circulating FFAs
Hepatic steatosis
Lipolysis
De novo lipogenesis
Insulin sensitivity
Circulating FFAs
Hepatic steatosis
Triglycerides
Cholesterol
Inflammation
Lipolysis
De novo lipogenesis
ROS
CRP
Insulin sensitivity
Inflammatory markers
Effect on Mitochondria
mtROS mtROS mtROS
mitochondrial biogenesis mitochondrial biogenesis mitochondrial biogenesis
mitochondrial respiration mitochondrial respiration mitochondrial respiration
References [188,190,191] [189,192,193] [194199]
Abbreviation:
NAFLD
: non-alcoholic fatty liver disease,
CVD
: cardiovascular disease,
FFAs
: free fatty acids,
ROS
:
reactive oxygen species,
CRP
: C-reactive protein,
mtROS
: mitochondrial reactive oxygen species,
ER: endoplasmic
reticulum, : increased, : decreased.
Mediterranean Diet and Beneficial Effects
The Mediterranean dietary pattern is particularly popular among people living in the
Mediterranean Sea basin. The MD is mainly characterized by a high intake of vegetables,
fruits, nuts, cereals, and whole grains, a moderate intake of white meat such as fish and
poultry, and low intake of dairy products, sweets, red meat, processed meat, and red
wine. Extra virgin olive oil becomes the principal source of fat [
200
203
] (Figure 2). The
promotion of a healthy lifestyle is an effective strategy is to decrease the risk of MetS
onset by promoting healthy lifestyle. Evidence suggests that the MD possesses antioxidant
and anti-inflammatory properties [
25
] with protective effects in regard to the disorders
associated with MetS and in the prevention of cardiovascular disease (CVD) [201].
Nutrients 2022, 14, x FOR PEER REVIEW 10 of 33
Abbreviation: NAFLD: non-alcoholic fatty liver disease, CVD: cardiovascular disease, FFAs: free
fatty acids, ROS: reactive oxygen species, CRP: C-reactive protein, mtROS: mitochondrial reactive
oxygen species, ER: endoplasmic reticulum, : increased, : decreased.
Mediterranean Diet and Beneficial Effects
The Mediterranean dietary pattern is particularly popular among people living in the
Mediterranean Sea basin. The MD is mainly characterized by a high intake of vegetables,
fruits, nuts, cereals, and whole grains, a moderate intake of white meat such as fish and
poultry, and low intake of dairy products, sweets, red meat, processed meat, and red
wine. Extra virgin olive oil becomes the principal source of fat [200–203] (Figure 2). The
promotion of a healthy lifestyle is an effective strategy is to decrease the risk of MetS onset
by promoting healthy lifestyle. Evidence suggests that the MD possesses antioxidant and
anti-inflammatory properties [25] with protective effects in regard to the disorders asso-
ciated with MetS and in the prevention of cardiovascular disease (CVD) [201].
Figure 2. The concept of the healthy food pyramid is based on differences across countries which
include food quality and quantity, social and cultural context, and economical aspects encountered
in the Mediterranean basin. The graphical abstracts provide information about the type of seasonal
food, weekly intake in relation to standard portions, and the role of macro- and micro-nutrients. The
idea is that of promoting healthy lifestyles among different populations. The importance of regular
physical activity and social relationships is also indicated. The final design of the MD pyramid today
and a brief complementary text for the general public have been developed by the Mediterranean
Diet Foundation Expert Group that includes the Mediterranean Diet Foundation’s International Sci-
entific Committee expertise, the in situ discussions by a representative group of members that met
within the Barcelona VIII International Congress on the Mediterranean diet, and several other ex-
perts who provided support on the design, editing, and translation to 10 different languages (Eng-
lish, French, Italian, Spanish, Catalan, Basque, Galician, Greek, Portuguese, and Arabic). With per-
mission from Cambridge University Press, 2022 [200]. Website http://dietamediterra-
nea.com/en/(accessed on 4 June 2022).
Figure 2.
The concept of the healthy food pyramid is based on differences across countries which
include food quality and quantity, social and cultural context, and economical aspects encountered
in the Mediterranean basin. The graphical abstracts provide information about the type of seasonal
food, weekly intake in relation to standard portions, and the role of macro- and micro-nutrients. The
Nutrients 2022,14, 3112 10 of 31
idea is that of promoting healthy lifestyles among different populations. The importance of regular
physical activity and social relationships is also indicated. The final design of the MD pyramid today
and a brief complementary text for the general public have been developed by the Mediterranean Diet
Foundation Expert Group that includes the Mediterranean Diet Foundation’s International Scientific
Committee expertise, the in situ discussions by a representative group of members that met within
the Barcelona VIII International Congress on the Mediterranean diet, and several other experts who
provided support on the design, editing, and translation to 10 different languages (English, French,
Italian, Spanish, Catalan, Basque, Galician, Greek, Portuguese, and Arabic). With permission from
Cambridge University Press, 2022 [
200
]. Website http://dietamediterranea.com/en/ (accessed on
4 June 2022).
Studies show that adherence to the MD has protective effects against obesity, stroke,
CVD, hypertension, diabetes, some types of cancer, allergic diseases, and Alzheimer and
Parkinson’s disease [
204
215
]. The American Diabetes Association and the American Heart
Association both recommend the MD in order to decrease cardiovascular risk factors in
T2DM and to improve glycemic control [
216
]. In younger subjects, low adherence to the
MD can trigger functional gastrointestinal symptoms, as component of the irritable bowel
syndrome and functional dyspepsia, mainly in younger subjects [
217
]. Unprocessed plant-
based food such as fruits, vegetables, legumes, seeds, spices, and nuts, rich in polyphenols,
are the principal aspect of the MD with a wide range of biological and pharmacological
effects [
218
221
]. The polyphenols undergo biotransformation process by gut microbiota
before reaching the liver by the portal vein with beneficial effects either locally (i.e., intes-
tine) and systemically (i.e., liver, brain) [
222
]. In contrast, the Western diet, high in calories,
is characterized by the high intake of processed macronutrients (cholesterol, fat, protein,
and sugars) and salt (sodium chloride), trans fats, and the low intake of fiber and magne-
sium. In the long term, this diet predisposes to obesity, insulin resistance, T2DM, CVD, and
MetS. At the molecular level, the Western diet stimulates oxidative stress and inflammation
by inducing mitochondrial dysfunction, decreasing the activity of antioxidant enzymes
such as catalase, dismutase, and glutathione peroxidase, and peroxisomal oxidation of fatty
acids [
223
]. As discussed earlier, the protective effects of the MD are the result of the diet
as a whole, rather than individual components, reinforcing the idea that the interaction
of various dietary components can have a beneficial synergistic effect [
222
]. However,
several scientific-based evidence about the beneficial effects of individual components of
the MD have been documented. For example, olive oil exerts antidiabetic, cardioprotective,
neuroprotective, and nephroprotective effects due to the presence of tyrosol, oleocanthal,
and hydroxytyrosol [
224
]. The long-term consumption of olive oil counteracts inflamma-
tion, promotes blood vessels’ relaxation, protects against T2DM, reduces blood pressure,
and increases insulin circulation [
225
]. The MD contains sea foods and fish rich in by
fatty acids such as docosahexaenoic acid (DHA) and eicosapentaenoic acids (EPAs), which
are metabolized producing 5-series leukotrienes and resolvins (RvE1 and RvE2). These
metabolites possess anti-inflammatory effects
in vivo
[
226
]. Red grapes and wine found in
the MD contain the polyphenol resveratrol (3,40,5-trihydroxystilbene), which not only has
cardioprotective, antiaging, and anticarcinogenic effects but also promotes neuroprotective
activities leading to anti-inflammatory, antioxidant, and gene-modulating effects. Resvera-
trol in patients with T2DM modulates the genes that influence mitochondrial function, such
as PGC-1
α
, which is a key regulator of mitochondrial biogenesis and leads to elevation of
mitochondrial content [
227
]. Furthermore, resveratrol indirectly activates AMP-activated
protein kinase (AMPK), leading to increased mitochondrial biogenesis, improved glucose
tolerance, insulin sensitivity, physical endurance, and a reduction in fat accumulation [
228
].
Moreover, due to its structural similarity to the synthetic estrogen diethylstilbesterol, resver-
atrol interacts with estrogen receptors inducing favorable cardiovascular effects. Several
studies have demonstrated that the overall pattern of the MD produces beneficial effects by
reducing the risk of obesity, hypertension, dyslipidemia, glucose metabolism, and CVD
in T2DM patients [
229
,
230
]. The MD includes a high consumption of green vegetables
Nutrients 2022,14, 3112 11 of 31
rich in magnesium, which is a main constituent of chlorophyll. The magnesium present in
chlorophyll plays a crucial role in the metabolism of insulin and glucose by translocating
the phosphate from ATP to protein through its influence on tyrosine kinase activity of the
insulin receptor. Magnesium is one of the cofactors of more than 300 enzymic reactions and
it is important for ATP metabolism. It is also necessary for the regulation of blood pressure,
insulin metabolism, muscle contraction, cardiac excitability, neuromuscular conduction,
and vasomotor tone. The deficiency of magnesium is known to be associated with the
onset of T2DM, while its consumption reduces the intensity of diabetes by sensitizing
insulin [231,232].
The MD also has significant protective effects in MetS [
19
,
233
]. Scientific-based ev-
idence suggest that many component of the MD display anti-inflammatory effects by
reducing the activation of NF-
κ
B signaling pathway and the expression of chemokine and
proinflammatory cytokines such as TNF-
α
, IL-1
β
, and IL-6 [
234
]. The decreased expression
of cytokines reduces oxidative stress, low-grade inflammation, and apoptotic cell death in
brain and visceral tissues [
235
]. Another biomarker for inflammation is C-reactive protein
(CRP), and prolonged intake of the MD diminishes CRP and unusual quantity of cytokines
and adipokines irrespective of weight loss increase [
235
237
]. Furthermore, the MD is
associated with lower mortality and a decreased incidence of common chronic diseases
such as CVD [
238
], several cancers [
239
], T2DM [
240
], fatty liver disease [
241
], and some
types of allergies [
242
] as a result of the inhibition of oxidative stress, reduction in inflamma-
tion, and improved lipid profiles [
218
,
219
,
243
245
]. Along with improving physical health,
long-term adherence to the MD also improves the quality of life and longevity [246,247].
5. MD and Mitochondrial Activity
5.1. Preclinical Studies
The MD is characterized by the high intake of several ingredients with beneficial,
nutraceutical and pharmaceutical properties, involved in the prevention and recovery of
metabolic diseases. This is achieved through different pathways, including the attenuation
of mitochondrial dysfunction (Table 3). Despite the difference in some components of the
MD between different countries, most essential ingredients are the same, such as olive oil,
PUFA (Omega-3), fruits, and polyphenol-rich plants and vegetables.
Table 3.
Summary of
in vitro
and
in vivo
studies about effects of Mediterranean diet on metabolic
diseases targeting mitochondria.
Compound Study Model Effects Reference
Chlorogenic Acid (CGA) In vitro
OxLDL-treated HUVECs
Oxidative Damage/Mitochondrial
Dysfunction
SIRT1 expression
OxLDL-impaired SIRT1 Level
ROS
SIRT1, AMPK, and PGC-1α
pathway
[248]
Delphinidin In vitro
VEGF-treated HUVECs Post-ischemic neovascularization
NRF1, Tfb2m, Tfam and PolG
Abnormal increase in
mitochondrial respiration,
mtDNA content, and complex IV
activity
[249]
Lycopene (LYC) In vivo
LPS-treated mice Inflammation
SIRT1
PGC1α
Cox5b, Cox7a1, Cox8b, and Cycs
Complexes I, II, III, and IV
[250]
Lycopene (LYC) In vitro
H2O2-treated SH-SY5Y Oxidative stress /Apoptosis
Depolarization
Bcl2
Bax
[251]
5-Heptadecylresorcinol
(AR-C17)
In vitro
H2O2-treated PC-12
Apoptosis/Mitochondrial
dysfunction
ROS
Mitochondrial respiration
ATP
SIRT-3
FOXO3a
H2O2-cell apoptosis
[252]
Nutrients 2022,14, 3112 12 of 31
Table 3. Cont.
Compound Study Model Effects Reference
Resveratrol In vivo
Mice Insulin resistance/Obesity
SIRT1 activity
PGC-1αactivity
Mitochondrial activity
Aerobic capacity
[253]
Resveratrol
In vitro
solubilized complex I
In vivo
Mice
Aging
Complex I activity in vitro
Complex I activity in young
mice
Oxidative stress in old mice
[227]
Resveratrol In vivo
HFD mice Obesity/Ageing
SIRT1 enzymatic activity
PGC-1αdeacetylation and
activity
[254]
Butyric acid In vivo
HFD mice Metabolic syndrome
PGC-1α
CPT1b
COX-I
PPAR-δ
Fatty acid oxidation
[255]
Butyrate and its synthetic
derivative FBA
In vivo
mice
In vitro
HepG2 cells
Insulin resistance/Obesity
Oxygen consumption
Citrate synthase activity
H2O2
Aconitase activity
Mfn1,Mfn2,Opa1
Drp1 and Fis1
[256]
Ginger extract (GE)/
6-gingerol
In vivo
mice
In vitro
HepG2 cells
-
mtDNA
OXPHOS
ATP
Complex I and IV activity
AMPK-PGC-1αsignaling
[257]
Ferulic acid (FA)
In vivo
HFD mice
In vitro
PBMC and EPC
Cardiovascular disease
Mitochondrial biogenesis
markers
Oxidative stress
PBMC apoptosis
PGC-1α
[258]
Different ω-3/ω-6 PUFAs
ratios
In vivo
mice Metabolic syndrome
Metabolic risk factors
p-mTOR
Mitochondrial electron transport
chain
Tricarboxylic acid cycle
Mitochondrial activities
Fumaric acid
Oxidative stress
[259]
Extra virgin olive oil
(EVOO) and
nitrite (NO3)
In vivo
mice NAFLD
HO-1 expression
Complexes II and V
NO2-OA
Cholesterol
LDL
Endothelial dysfunction
Blood pressure
Thrombosis
Hyperglycemia
[260]
Hydroxytyrosol (HT) In vivo
mice Metabolic syndrome
Drp1
Complex I and II
Complex V
PARP
[261]
Hydroxytyrosol (HT)
In vivo
HFD-Megalobrama amblycephala
fish
In vitro
hepatocytes
Hepatic fat deposition
Citrate synthase activity
ATP content
Mitochondria number
PGC-1α, PGC-1β, NRF1 and
TFAM
[262]
Ellagic acid (EA) In vivo
chronic arsenic-rats Diabetes/Cancer
ROS
Mitochondrial damage
Dehydrogenase complex
II-associated activity
[263].
Apigenin (APG)
In vivo
multiwall CNT
(MWCNT)-exposed rats
Kidney toxicity
Succinate dehydrogenase
ROS
Mitochondrial membrane
potential
Mitochondrial swelling
Release cytochrome
[264]
Apigenin (APG) In vivo
aged Mice Muscle Atrophy
Basal oxygen consumption
Complexes I, II, and IV activity
ATP content
PGC-1α, TFAM, and NRF-1
Cyt-C release to cytosol
[265]
Nutrients 2022,14, 3112 13 of 31
Table 3. Cont.
Compound Study Model Effects Reference
Cocoa Flavanols In vivo
mice
Healthy and
SIRT3-/-mice
Mitochondrial respiration
AMPK phosphorylation
Mitochondria mass
NAD+/NADH
Complex I and IV activity
[266]
Abbreviations: Drp1
: mitochondrial fission-related protein,
Bak, Bax, and Bad
: proapoptotic Bcl-2 members,
Bcl-2 and Bcl-XL
: antiapoptotic Bcl-2 proteins,
PARP
: poly(ADP-ribose) polymerase,
HFD
: high-fat diet,
EVOO
:
extra virgin olive oil,
HO-1
: heme oxygenase-1,
NO2-OA
: nitro-fatty acids,
LDL
: low-density lipoprotein,
LYC
:
lycopene,
SH-SY5Y
: human neuroblastoma cells
LPS
: lipopolysaccharides,
SIRT1
: sirtuin 1,
PGC1α
: perox-
isome proliferator–activated receptor gamma coactivator-1
α
,
Cox
: cyclooxygenase,
PBMC
: peripheral blood
mononuclear cell,
EPC
: endothelial progenitor cells,
ROS
: reactive oxygen species,
HUVECs
: human umbilical
vein endothelial cells,
OxLDL
: oxidized low-density lipoprotein,
FOXO3a
: forkhead box O3 (transcription fac-
tors),
HepG2
: human liver cancer cell line,
OXPHOS
: oxidative phosphorylation,
NAD+
: nicotinamide adenine
dinucleotide,
CPT1b
: carnitine palmitoyltransferase 1B,
COX-1
: cytochrome c oxidase I,
PPAR-δ
: peroxisome
proliferator–activated receptor-
δ
,
FBA
:N-(1-carbamoyl-2-phenyl-ethyl) butyramide,
MetS
: metabolic syndrome,
: increased, : decreased.
In vitro
studies evaluated the beneficial effects of polyphenol-rich foods on MetS
mediating mitochondrial modulation. In detail, the protective role of chlorogenic acid
(CGA) found in coffee beans and apples against ox-LDL-induced endothelial cells dys-
function as cellular model of atherosclerosis was evaluated using human endothelial cells
HUVECs. CGA displayed mitochondria-mediated effects by enhancing SIRT1 activity
and up-regulating AMPK and PGC-1 expression to maintain mitochondrial biogenesis. In
addition, CGA treatment exhibited a cytoprotective effect by reducing ROS production
in endothelial cells. [
248
]. Similarly, in endothelial cells with VEGF-induced mitochon-
drial dysfunction, delphinidin (a flavonoid present in red wine and berries) restored the
elevated level of mitochondrial respiration, mtDNA content, and complex IV activity. In
addition, delphinidin increased the expression of NRF1, Tfb2m, Tfam, and PolG, all of
which are involved in the regulation of mitochondrial biogenesis [
249
]. Lycopene (LYC), a
member of the carotene phytochemical family, present in tomatoes and grapefruits, exerted
an anti-inflammatory effect on mice exposed to LPS through improving mitochondrial
dysfunction. In detail, LYC upregulated the expression of SIRT1, PGC1
α
, Cox5b, Cox7a1,
Cox8b, and Cycs. In addition, a partial effect of LYC was proved in regulating the expres-
sion of many complexes in the respiratory chain [
250
]. Another
in vitro
study using human
neuroblastoma cells SH-SY5Y showed a protective effect of lycopene against H
2
O
2
-induced
depolarization of the mitochondrial membrane [
251
]. LYC increased the expression of Bcl2
and decreased Bax expression [
251
]. Whole grains also represent an important category in
the MD, with a beneficial impact on metabolic diseases. Especially, 5-heptadecylresorcinol,
a biomarker of whole grain rye consumption, protects against H
2
O
2
-induced oxidative
stress in rat pheochromocytoma (PC-12) by activating the SIRT3-FOXO3a signaling path-
way. In addition, it reduced mitochondrial ROS levels and maintained the mitochondrial
respiration and membrane potential, which leads to an increase in ATP production and cell
respiration [252].
Another study found that the antioxidant effect of resveratrol found in grapes, berries,
and cacao is dose- and age-dependent [
253
]. This polyphenol competes with NAD+ in a
solubilized complex of mitochondria to improve their activity [
253
]. In addition, resveratrol
prevents metabolic diseases (obesity and insulin resistance) in mice through improving
mitochondrial function via PGC-1
α
and SIRT-1 activation [
227
]. These results have also been
confirmed by Baur et al. [
254
] using a high-calorie-diet mice model which demonstrated
a SIRT-1-dependent effect of resveratrol on the activation of PGC-1
α
resulting in the
improvement of mitochondrial biogenesis.
By monitoring the increase in CO
2
level in skeletal muscle tissue and L6 muscle cells
in butyrate-treated mice, an increase in PGC-1
α
level accompanied by an increase in CPT1b
and COX-I genes expression was observed. Moreover, the levels of peroxisome proliferator
activated receptors (PPARs) were also increased in the treated group. Overall, these data
suggest that butyrate (found in legumes, fruits, and nuts) promotes fatty acid oxidation
Nutrients 2022,14, 3112 14 of 31
and improves mitochondrial function [
255
]. In addition, butyrate increased citrate synthase
activity, aconitase activity, and oxygen consumption in butyrate-treated mice and FBA-
treated human HepG2 cells, with a decrease in H
2
O
2
yield. In mitochondrial dynamics,
butyrate and FBA upregulated the expression of fusion genes (Mfn1,Mfn2, and Opa1) and
decreased the expression of fission-related genes (Drp1 and Fis1) [256].
Ginger extract and its bioactive compound 6-gingerol promote mitochondrial biogen-
esis and function through improving AMPK-PGC1
α
signaling
in vivo
(skeletal muscle,
liver, and BAT) and
in vitro
(HepG2 cells). Furthermore, 6-gingerol enhanced p-AMPK
α
,
PGC-1
α
, NRF1, and TFAM protein expression and stimulated the subunits of OXPHOS
complexes in HepG2 cells [
257
]. Further study links the role of ferulic acid (FA), the main
active phenolic acid in rice bran, with the improvement of mitochondrial biogenesis and
dynamic by increasing the expression of Pgc-1
α
,Pgc-1
β
,Nrf-1,Mfn1,Mfn2,Fis1, and Beclin-
1. In addition, the rice bran enzymatic extract (RBEE) diet upregulated AMPK activity with
enhanced PGC-1
α
expression in mice. The latter was also observed in peripheral blood
mononuclear cell (PBMC) and endothelial progenitor cells (EPC), in addition to an increase
in fusion MFN1 [258].
The effect of a high omega-3 to omega-6 ratio (
ω
-3/
ω
-6) on metabolic syndrome was
investigated
in vivo
using high-fat-diet mice. A high
ω
-3/
ω
-6 ratio significantly decreased
the insulin index, body weight, atherosclerosis markers, and accumulation of hepatic lipid.
These effects were mediated by a reduction in p-mTOR expression, accompanied by an
upregulation of the mitochondrial electron-transport chain and tricarboxylic acid-cycle
pathway, when compared to a diet with a low or moderate
ω
-3/
ω
-6 ratio. Therefore, a
diet with a high
ω
-3/
ω
-6 ratio displayed an enhancement of mitochondrial complexes
activities, accompanied by an alleviation of fumaric acid and oxidative stress [
259
]. The
Mediterranean diet also contains a variety of vegetables rich in NO
2
and nitrate (NO
3
).
Sánchez-Calvo et al. analyzed the involvement of nitro-fatty acids (NO
2
-FA) on the benefi-
cial effects of extra virgin olive oil (EVOO) consumption on an NAFLD experimental animal
model. EVOO and nitrite supplementation improved the function of liver mitochondrial
complexes II and V and exerted antioxidant and anti-inflammatory effects. The authors
concluded that EVOO-NO
2
consumption may promote additional nutraceutical effects in
NAFLD patients [260].
Hydroxytyrosol (HT), a polyphenol from olive oil, was effective in the regulation
of multiple HFD-induced MetS, especially those related to mitochondrial dysfunction,
through the modulation of mitochondrial apoptotic pathway in the liver and skeletal mus-
cles. Moreover, HT treatment normalized the down-expression of Complex I and II and the
up-expression of complex V, while Drp1 and PARP were decreased after treatment [
261
].
HT may also improve mitochondrial biogenesis (increase mtDNA and number of mito-
chondria) through the AMPK pathway, by enhancing the expression of involved genes
(PGC-1
α
, NRF-1, and TFAM). ATP content and citrate synthase activity were also shown
to increase after HT treatment of HFD (high-fat diet) and LFD (low-fat diet) groups [
262
].
Another phenolic acid, ellagic acid, which is found in strawberries and walnuts, prevents
metabolic disorders by targeting the mitochondria via two ways: directly, by decreasing
the ROS amounts and mitochondrial damage, or indirectly, by restoring the total dehydro-
genase activity in mitochondria through complex II maintenance [
263
]. Apigenin (APG),
a flavonoid found in many fruits and vegetables, increased the respiratory complex II
succinate dehydrogenase (SDH) activity on carbon-nanotubes-induced mitochondrial dam-
age. APG acts as antioxidant by decreasing ROS generation in kidney, which leads to a
decrease in MMP collapse [
264
]. Results were confirmed in another study in old mice
by Wang et al. [
265
]. In addition, APG improves mitochondrial biogenesis (by increasing
mtDNA, PGC-1α, TFAM, and NRF-1), and the activity of complexes I, II, and IV and ATP
synthesis [
265
]. Cocoa flavanol supplementation boosted the NAD metabolism, which
stimulates sirtuins metabolism and improved mitochondrial function. These results suggest
that flavanols likely contributed to the observed whole-body metabolism adaptation, with
a greater ability to use carbohydrates, at least partially through Sirt3 [266].
Nutrients 2022,14, 3112 15 of 31
5.2. Clinical Studies
In subjects with NASH, a six-month treatment with omega-3 showed a regulation of
lipogenesis, ER stress, and mitochondrial function [
267
]. These effects were mediated by an
overexpression of FABPL and PRDX6, with a reduction in PGRMC1 level. Meanwhile, an
up-representation of PEBP1 and ApoJ was detected after the oral consumption of omega-3,
confirming its role in the modulation of insulin resistance. In addition, FASTKD2, mitochon-
drial proteins related to aerobic-cell respiration, was overexpressed in this situation [
267
].
A study in patients on 2–3 weeks of a PUFA diet before elective cardiac surgery confirmed
that omega-3 fatty acids from fish oil upregulated the nuclear transactivation of peroxisome
proliferator–activated receptor-
γ
(PPAR
γ
). This effect improved the mitochondrial oxida-
tion of fatty acid and enhanced the antioxidant effect in the human atrial myocardium [
268
].
An EPA+DHA diet increases the expression of mitochondrial uncoupling protein 3 (UCP3)
and ubiquinol cytochrome c reductase (UQCRC1) genes, which reduces ROS production.
In addition, this diet improved oxidative phosphorylation activity and the extracellular
matrix (ECM)-related pathways [
269
]. DHA, an omega 3 fatty acid, present in marine
foods, increases the expression of the genes responsible for integrating fatty acid into
mitochondria, as a new source of energy. In addition, DHA-enriched food consumption
enhanced mitochondrial antioxidant capabilities and decreased mitochondrial ROS produc-
tion [
270
]. The effect of resveratrol was studied in overweight/T2DM patients. Resveratrol
improves the mitochondrial function through increasing state 3 respiration, while decreas-
ing complex IV [
271
]. Resveratrol can stimulate the ENDOG gene to further stimulate the
PGC-1
α
activity in biogenesis and to increase the number of mitochondria [
272
]. Resvera-
trol combined with epigallocatechin-3-gallate (EGCG) increases complexes III and V and
improves the electron transport chain capacity, in addition to the upregulation of the citric
acid cycle and fat oxidation in muscles during fasting [
273
]. Furthermore, a mixture of
ancient peat and apple extract exerts a beneficial effect on mitochondrial function and
ATP production, accompanied with a decrease in ROS production and oxidative stress in
resistance-trained [274] (Table 4).
Table 4.
Clinical studies in metabolic syndrome assessing the efficacy of MD components on mitochondria.
Authors Year Sample Size Gender M/F
(Age) Participants Format, Dose Duration of Study Main Findings
Anderson et al.
[268]2014 24 16/8
(63.1 ±8.4; 65.8 ±9.9)
Elective cardiac
surgery for patients
Oral consumption
of EPA and DHA
capsule,
3.4 g/day
2–3 weeks
PPARγ
Mitochondrial
fatty acid oxidation
TxnRd2 enzyme
Capo et al.
[270]2014 15 15/0
(20.4 ±0.5)
Exercise-induced
oxidative stress
Beverage enriched
with DHA 2 months
Antioxidant
activity
ROS production
DHA
Yoshino et al.
[269]2016 20 60 to 85 Large hypertrophic
response
Consumption of 4
pills (1.86g EPA+
1.50 g DHA)
6 months
Respiratory
electron transport
activity
Oxidative
phosphorylation
ECM
organization
UCP3 and
UQCRC1
Most et al.
[273]2016 38 18/20 (38 ±2) Subjects with
obesity
Consumption of
282 mg EGCG + 80
mg RES
12 weeks
Complexes III
and V
Citric acid cycle
Respiratory
electron-transport
chain
Fat oxidation
Joy et al. [274] 2016 25 25/0 (28 ±5) Resistance-trained
subjects
Consumption of
150 mg (ancient
peat and apple
extract (TRT))
12 weeks
Mitochondrial
ATP production
ROS
Oxidative stress
Nutrients 2022,14, 3112 16 of 31
Table 4. Cont.
Authors Year Sample Size Gender M/F
(Age) Participants Format, Dose Duration of Study Main Findings
Pollack et al.
[272]2017 30 19/11
(67 ±7)
Older
glucose-intolerant
patients
Treated with 23 g
Resveratrol/day 6 weeks
Mitochondrial
number
Oxidative
phosphorylation
ENDOG
P GC1α
Samara et al.
[267]2018 60 18–75 years Patients with
NASH
Oral consumption
of n 3 PUFA
capsules, 0.945
g/day
6 months
ALA, EPA, glyc-
erophospholipids
Arachidonic acid
FABPL
PRDX6
PGRMC1
PEBP1, ApoJ
FASTKD2
de Ligt et al.
[271]2018 13 13/0
(59.2 to 67.6)
Patients with
overweight/T2DM
Consumption of
150 mg
Resveratrol/day
6 months
State 3
respiration
Complex IV
Mitochondrial
function
Abbreviations: ALA
: alpha-linolenic acid,
EPA
: eicosapenteanoic acid,
FABPL
: fatty acid binding protein—liver
type,
PRDX6
: peroxiredoxin 6,
PEBP1
: phosphatidylethanolamine-binding protein 1,
ApoJ
: apolipoprotein J,
FASTKD2
: FAST kinase domain-containing protein 2,
PGRMC1
: progesterone receptor membrane component
1 protein,
DHA
: doxosahexaenoic acid,
ECM
: extracellular matrix,
UCP3
: l uncoupling protein 3,
UQCRC1
:
ubiquinol cytochrome c reductase,
EGCG
: epigallocatechin-3-gallate,
RES
: resveratrol,
ENDOG
: endonuclease G,
: increased, : decreased.
6. Summary
Mitochondrial dysfunction can occur along with many diseases, and the dysfunction is
associated with changes in gene expression reflecting on both cell morphology and function.
Key events include disrupted mitochondrial ATP production, impaired metabolism, and
regulation of apoptosis. Altered metabolic homeostasis will also influence the physiological
mitochondrial dynamics. [
275
]. In the last decade, so-called mitochondrial medicine and
mitochondrial nutrients have attracted the attention of researchers, with the idea that
improving mitochondrial structure and function is a plausible strategy for MetS prevention
and treatment. It is important to note that the MD is rich in polyphenols and other naturally
derived compounds that have substantial antioxidant properties, the capacity to scavenge
free radicals, and the ability to modulate endogenous antioxidant defense mechanisms.
These effects involve mitochondrial antioxidant enzymes. Due to their antioxidant proper-
ties, polyphenols can reduce the inflammation and mitochondrial dysfunction characteristic
of MetS. Hereby, we discussed the effects of the main nutrients and polyphenols in the
MD on mitochondrial dysfunction in MetS. Preclinical studies (
in vitro
cellular and
in vivo
animal studies) show that the nutrients and polyphenols present in the MD, such as chloro-
genic acid, resveratrol, hydroxytyrosol, and apigenin, exert a vast range of beneficial effects
on mitochondrial dysfunction. Figure 3summarizes the possible mechanisms, including
the effects on key regulators of mitochondrial function and biogenesis such as SIRT-1,
AMPK, and PGC-1
α
. In addition, the antioxidant properties of the polyphenols present in
the MD reduced mtROS production and ameliorated mitochondrial damage and apoptosis
in different experimental studies. Several studies reported the health-promoting effects of
the MD due to its high fiber content.
Short-chain fatty acids are the end products of the fermentation of insoluble fiber by
the gut microbiota. Evidence suggests SCFAs can modulate several metabolic disorders
such as obesity, insulin resistance, and T2DM [276]. Butyrate, an SCFA present in the MD,
promotes fatty acid oxidation and improves mitochondrial function. The vegetables, nuts,
and fish characteristics of the MD contain significant amounts of PUFA. The correlation
between PUFA intake (especially
ω
-3) and decreased cardiometabolic risk has been well-
documented [
277
]. Additionally, dietary n-3 PUFAs have shown substantial positive
effects on mitochondrial function and structure [
278
]. These effects seem to be mediated
by a reduction in the expression of p-mTOR, accompanied by the upregulation of the
mitochondrial electron-transport chain and tricarboxylic acid cycle. Several studies in
Nutrients 2022,14, 3112 17 of 31
humans have demonstrated the beneficial effect of the bioactive compounds present in
the MD on MetS, suggesting advanced health-promoting effects through the targeting of
mitochondria. This could be used to promote additional pharmacological and nutraceutical
effects, especially on the gastrointestinal system and muscle strength.
Nutrients 2022, 14, x FOR PEER REVIEW 18 of 33
6. Summary
Mitochondrial dysfunction can occur along with many diseases, and the dysfunction
is associated with changes in gene expression reflecting on both cell morphology and
function. Key events include disrupted mitochondrial ATP production, impaired
metabolism, and regulation of apoptosis. Altered metabolic homeostasis will also
influence the physiological mitochondrial dynamics. [276]. In the last decade, so-called
mitochondrial medicine” and “mitochondrial nutrients have attracted the attention of
researchers, with the idea that improving mitochondrial structure and function is a
plausible strategy for MetS prevention and treatment. It is important to note that the MD
is rich in polyphenols and other naturally derived compounds that have substantial
antioxidant properties, the capacity to scavenge free radicals, and the ability to modulate
endogenous antioxidant defense mechanisms. These effects involve mitochondrial
antioxidant enzymes. Due to their antioxidant properties, polyphenols can reduce the
inflammation and mitochondrial dysfunction characteristic of MetS. Hereby, we
discussed the effects of the main nutrients and polyphenols in the MD on mitochondrial
dysfunction in MetS. Preclinical studies (in vitro cellular and in vivo animal studies) show
that the nutrients and polyphenols present in the MD, such as chlorogenic acid,
resveratrol, hydroxytyrosol, and apigenin, exert a vast range of beneficial effects on
mitochondrial dysfunction. Figure 3 summarizes the possible mechanisms, including the
effects on key regulators of mitochondrial function and biogenesis such as SIRT-1, AMPK,
and PGC-1α. In addition, the antioxidant properties of the polyphenols present in the MD
reduced mtROS production and ameliorated mitochondrial damage and apoptosis in
different experimental studies. Several studies reported the health-promoting effects of
the MD due to its high fiber content.
Figure 3. Potential molecular mechanisms of MD on mitochondrial dysfunction in MetS. The dotted
red line represents inhibitory pathways. Abbreviations: AMPK: AMP-activated protein kinase;
BAX: bcl2-like protein 4; Bcl2: B-cell lymphoma 2; NRF1: nuclear respiratory factor 1; PPARs:
peroxisome proliferator–activated receptors; PGC1α: peroxisome proliferator–activated receptor-
gamma coactivator-1α; SIRT1: sirtuin 1; TFAM: transcription factor A, mitochondrial.
Short-chain fatty acids are the end products of the fermentation of insoluble fiber by
the gut microbiota. Evidence suggests SCFAs can modulate several metabolic disorders
Figure 3.
Potential molecular mechanisms of MD on mitochondrial dysfunction in MetS. The dotted
red line represents inhibitory pathways. Abbreviations: AMPK: AMP-activated protein kinase;
BAX: bcl2-like protein 4; Bcl
2: B-cell lymphoma 2; NRF
1: nuclear respiratory factor 1; PPARs:
peroxisome proliferator–activated receptors; PGC
1
α
: peroxisome proliferator–activated receptor-
gamma coactivator-1α; SIRT1: sirtuin 1; TFAM: transcription factor A, mitochondrial.
7. Conclusions
Obesity is closely linked to metabolic disorders that pave the way for organ, tissue,
cellular, and sub-cellular dysfunction. Mitochondria are dynamic cell organelles, which are
essential for energy metabolism and represent cardinal players in obesity and metabolic
disease. Cumulative evidence from pre-clinical studies indicates that the MD is rich in
polyphenols, essential oils, and fiber and plays a beneficial role by stimulating mitochon-
drial biogenesis and exerting an antioxidant effect.
Despite the substantial positive effects reported for the MD and its components in
obesity and MetS, the bioactive mechanisms of the MD on mitochondrial dysfunction
are not fully understood. Therefore, further animal and human studies are necessary to
elucidate the translational aspects of “mitochondrial nutrition” and to fully characterize its
role in the prevention and treatment of obesity-related MetS.
Author Contributions:
Conceptualization, H.S. and P.P.; writing—original draft preparation, H.S.,
H.A., J.S.J.B. and I.G.; revision, J.G.-A., G.F., M.K. and P.P. All authors have read and agreed to the
published version of the manuscript.
Funding:
This paper has been partly supported by funding from the European Union’s Horizon
2020 Research and Innovation program under the Marie Skłodowska-Curie Grant Agreement No.
722619 (FOIE GRAS), Grant Agreement No. 734719 (mtFOIE GRAS), Grant Regione Puglia, CUP
H99C20000340002 (Fever Apulia), and Grant EUROSEEDS Uniba—S56—By-Products Sustainable
Recovery 4 Health (BSR-4H): University of Bari Aldo Moro, 2022.
Institutional Review Board Statement: Not applicable.
Nutrients 2022,14, 3112 18 of 31
Informed Consent Statement: Not applicable.
Acknowledgments:
The authors are indebted to Rosa De Venuto, Paola De Benedictis, Domenica Di
Palo, Ilaria Farella, and Elisa Lanza for their skillful technical assistance and to Danute Razuka-Ebela
for their English-language revision.
Conflicts of Interest: The authors declare no conflict of interest.
Abbreviations
ATP Adenosine triphosphate
ATP III Adult Treatment Panel III
AMPK AMP-activated protein kinase
APG Apigenin
ApoJ Apolipoprotein J
BMI Body mass index
Bcl2 B-cell lymphoma 2
Bax BCl2-associated X
CV Cardiovascular
CoQ Coenzyme Q
CoA Coenzyme A
CPT-1 Carnitine palmitoyltransferase-1
CYP2E1 Mitochondrial Cytochrome P450 2E1
CVD Cardiovascular disease
CRP C-reactive protein
CGA Chlorogenic acid
Cox Cytochrome C oxidase
Cycs Cytochrome C
CO2Carbon dioxide
CPT1b Carnitine palmitoyltransferase 1B
DNA Deoxyribonucleic acid
DHAs Docosahexaenoic acids
Drp1 Dynamin-related protein 1
DHA Doxosahexaenoic acid
ETC Electron transport chain
ERR Estrogen-related receptors
EPAs Eicosapentaenoic acids
EPC Endothelial progenitor cells
EVOO Extra virgin olive oil
ER stress Endoplasmic reticulum stress
EPA Eicosapenteanoic acid
ECM Extracellular matrix
EGCG Epigallocatechin-3-gallate
ENDOG Endonuclease G
FAD Flavin adenine dinucleotide
FFA Free fatty cid
FOXO3a Forkhead box O3 (transcription factors)
FBA N-(1-carbamoyl-2-phenyl-ethyl)
butyramide
Fis1 Mitochondrial fission protein1
Nutrients 2022,14, 3112 19 of 31
FA Ferulic acid
FABPL Fatty acid binding protein—liver type
FASTKD2 FAST kinase domain-containing protein 2
H2O2 Hydrogen peroxide
HFD High-fat diet
HUVECs Human endothelial cells
HT Hydroxytyrosol
HepG2 Human liver cancer cell line
HDL High-density lipoprotein
IDF International Diabetes Federation
IMM Inner mitochondrial membrane
IL-1βInterleukin 1 beta
IL-6 Interleukin 6
LYC Lycopene
LFD Low-fat diet
MetS Metabolic Syndrome
MD Mediterranean diet
MHO Metabolically healthy obesity
MAO Metabolically altered obesity
MAFLD Metabolic dysfunction associated fatty liver disease
mtROS Mitochondrial reactive oxygen species
mtDNA Mitochondrial Deoxyribonucleic Acid
Mfn1 Mitofusin-1
Mfn2 Mitofusin-2
MWCNTs Multi-walled carbon nanotubes
NAFLD Non-alcoholic fatty liver disease
NAD Nicotinamide adenine dinucleotide
NRF Nuclear respiratory factors
NRF-1 Nuclear respiratory factor 1
NASH Non-alcoholic steatohepatitis
NADPH Nicotinamide adenine dinucleotide phosphate oxidase
NF-κB Nuclear factor kappa-light-chain-enhancer of activated B cells
NO2-OA Nitro-fatty acids
OMM Outer mitochondrial membrane
OXPHOS Oxidative phosphorylation
ox-LDL Oxidized low-density lipoprotein
PGC-1αPeroxisome proliferator–activated receptor gamma coactivator-1 α
PUFA Polyunsaturated fatty acid
PPAR-αPeroxisome proliferator–activated receptor-α
PolG DNA polymerase subunit gamma
PC-12 Pheochromocytoma
PBMC Peripheral blood mononuclear cell
PRDX6 Peroxiredoxin 6
Nutrients 2022,14, 3112 20 of 31
PGRMC1 Progesterone receptor membrane component 1 protein
PEBP1 Phosphatidylethanolamine-binding protein 1
ROS Reactive oxidative atress
RBEE Rice bran enzymatic extract
SO Sarcopenic obesity
SIRT1 Sirtuin 1
SH-SY5Y Human neuroblastoma cells
SDH Succinate dehydrogenase
SCFAs Short-chain fatty acids
T2DM Type 2 diabetes mellitus
TOFI Thin-outside-fat-inside
t-RNA Transfer ribonucleic acid
TFAM Mitochondrial transcription factor A
TFB2M Mitochondrial transcription factor B2
TNF-αTumor necrosis factor
Tfb2m Transcription factor B2, mitochondria
UCP3 Uncoupling protein 3
UQCRC1 Ubiquinol cytochrome c reductase
VEGF Vascular endothelial growth factor
WHO World Health Organization
References
1.
Di Ciaula, A.; Krawczyk, M.; Filipiak, K.J.; Geier, A.; Bonfrate, L.; Portincasa, P. Noncommunicable diseases, climate change and
iniquities: What COVID-19 has taught us about syndemic. Eur. J. Clin. Investig. 2021,51, e13682. [CrossRef]
2.
Chaudhuri, R.; Thompson, M.A.; Pabelick, C.; Agrawal, A.; Prakash, Y.S. Obesity, mitochondrial dysfunction, and obstructive
lung disease. In Mechanisms and Manifestations of Obesity in Lung Disease; Johnston, R.A., Suratt, B.T., Eds.; Academic Press:
Cambridge, MA, USA, 2019; pp. 143–167.
3.
Mitchell, T.; Darley-Usmar, V. Metabolic syndrome and mitochondrial dysfunction: Insights from preclinical studies with a
mitochondrially targeted antioxidant. Free Radic. Biol. Med. 2012,52, 838–840. [CrossRef]
4.
Isomaa, B.; Almgren, P.; Tuomi, T.; Forsen, B.; Lahti, K.; Nissen, M.; Taskinen, M.R.; Groop, L. Cardiovascular morbidity and
mortality associated with the metabolic syndrome. Diabetes Care 2001,24, 683–689. [CrossRef]
5. Reaven, G.M. Banting lecture 1988. Role of insulin resistance in human disease. Diabetes 1988,37, 1595–1607. [CrossRef]
6.
Rogge, M.M. The role of impaired mitochondrial lipid oxidation in obesity. Biol. Res. Nurs.
2009
,10, 356–373. [CrossRef]
[PubMed]
7.
Osellame, L.D.; Blacker, T.S.; Duchen, M.R. Cellular and molecular mechanisms of mitochondrial function. Best Pract. Res. Clin.
Endocrinol. Metab. 2012,26, 711–723. [CrossRef]
8.
Kusminski, C.M.; Scherer, P.E. Mitochondrial dysfunction in white adipose tissue. Trends Endocrinol. Metab. TEM
2012
,
23, 435–443
.
[CrossRef]
9.
Bournat, J.C.; Brown, C.W. Mitochondrial dysfunction in obesity. Curr. Opin. Endocrinol. Diabetes Obes.
2010
,17, 446–452.
[CrossRef]
10. Brand, M.D.; Nicholls, D.G. Assessing mitochondrial dysfunction in cells. Biochem. J. 2011,435, 297–312. [CrossRef]
11.
Liesa, M.; Shirihai, O.S. Mitochondrial dynamics in the regulation of nutrient utilization and energy expenditure. Cell Metab.
2013,17, 491–506. [CrossRef]
12.
Zorzano, A.; Liesa, M.; Palacin, M. Role of mitochondrial dynamics proteins in the pathophysiology of obesity and type 2 diabetes.
Int. J. Biochem. Cell Biol. 2009,41, 1846–1854. [CrossRef] [PubMed]
13.
Yin, X.; Lanza, I.R.; Swain, J.M.; Sarr, M.G.; Nair, K.S.; Jensen, M.D. Adipocyte mitochondrial function is reduced in human
obesity independent of fat cell size. J. Clin. Endocrinol. Metab. 2014,99, E209–E216. [CrossRef]
14.
Putti, R.; Sica, R.; Migliaccio, V.; Lionetti, L. Diet impact on mitochondrial bioenergetics and dynamics. Front. Physiol.
2015
,6, 109.
[CrossRef]
15.
Heinonen, S.; Buzkova, J.; Muniandy, M.; Kaksonen, R.; Ollikainen, M.; Ismail, K.; Hakkarainen, A.; Lundbom, J.; Lundbom, N.;
Vuolteenaho, K.; et al. Impaired Mitochondrial Biogenesis in Adipose Tissue in Acquired Obesity. Diabetes
2015
,64, 313–3145.
[CrossRef] [PubMed]
Nutrients 2022,14, 3112 21 of 31
16.
Simopoulos, A.P. The importance of the omega-6/omega-3 fatty acid ratio in cardiovascular disease and other chronic diseases.
Exp. Biol. Med. 2008,233, 674–688. [CrossRef]
17.
Marventano, S.; Kolacz, P.; Castellano, S.; Galvano, F.; Buscemi, S.; Mistretta, A.; Grosso, G. A review of recent evidence in human
studies of n-3 and n-6 PUFA intake on cardiovascular disease, cancer, and depressive disorders: Does the ratio really matter? Int.
J. Food Sci. Nutr. 2015,66, 611–622. [CrossRef]
18. Huo, R.; Du, T.; Xu, Y.; Xu, W.; Chen, X.; Sun, K.; Yu, X. Effects of Mediterranean-style diet on glycemic control, weight loss and
cardiovascular risk factors among type 2 diabetes individuals: A meta-analysis. Eur. J. Clin. Nutr.
2015
,69, 1200–1208. [CrossRef]
19.
Kastorini, C.M.; Milionis, H.J.; Esposito, K.; Giugliano, D.; Goudevenos, J.A.; Panagiotakos, D.B. The effect of Mediterranean diet
on metabolic syndrome and its components: A meta-analysis of 50 studies and 534,906 individuals. J. Am. Coll. Cardiol.
2011
,
57, 1299–1313. [CrossRef] [PubMed]
20.
Rees, K.; Hartley, L.; Clarke, A.; Thorogood, M.; Stranges, S. ‘Mediterranean’ dietary pattern for the primary prevention of
cardiovascular disease. Cochrane Database Syst. Rev. 2012,8, CD009825. [CrossRef]
21.
Rosato, V.; Temple, N.J.; La Vecchia, C.; Castellan, G.; Tavani, A.; Guercio, V. Mediterranean diet and cardiovascular disease: A
systematic review and meta-analysis of observational studies. Eur. J. Nutr. 2019,58, 173–191. [CrossRef]
22.
Estruch, R.; Ros, E.; Salas-Salvado, J.; Covas, M.I.; Corella, D.; Aros, F.; Gomez-Gracia, E.; Ruiz-Gutierrez, V.; Fiol, M.;
Lapetra, J.; et al
. Primary Prevention of Cardiovascular Disease with a Mediterranean Diet Supplemented with Extra-Virgin
Olive Oil or Nuts. N. Engl. J. Med. 2018,378, e34. [CrossRef] [PubMed]
23.
Dontas, A.S.; Zerefos, N.S.; Panagiotakos, D.B.; Vlachou, C.; Valis, D.A. Mediterranean diet and prevention of coronary heart
disease in the elderly. Clin. Interv. Aging 2007,2, 109–115. [CrossRef] [PubMed]
24.
Laubinger, W.; Dimroth, P. Characterization of the ATP synthase of Propionigenium modestum as a primary sodium pump.
Biochemistry 1988,27, 7531–7537. [CrossRef]
25.
Medina-Remon, A.; Casas, R.; Tressserra-Rimbau, A.; Ros, E.; Martinez-Gonzalez, M.A.; Fito, M.; Corella, D.; Salas-Salvado, J.;
Lamuela-Raventos, R.M.; Estruch, R.; et al. Polyphenol intake from a Mediterranean diet decreases inflammatory biomarkers
related to atherosclerosis: A substudy of the PREDIMED trial. Br. J. Clin. Pharm. 2017,83, 114–128. [CrossRef]
26.
World Health Organization. Fact Sheet: Obesity and Overweight. Available online: http://apps.who.int/bmi/index.jsp?
introPage=intro_3.html (accessed on 15 June 2022).
27.
Schwartz, M.W.; Seeley, R.J.; Zeltser, L.M.; Drewnowski, A.; Ravussin, E.; Redman, L.M.; Leibel, R.L. Obesity Pathogenesis: An
Endocrine Society Scientific Statement. Endocr. Rev. 2017,38, 267–296. [CrossRef]
28.
Upadhyay, J.; Farr, O.; Perakakis, N.; Ghaly, W.; Mantzoros, C. Obesity as a Disease. Med. Clin. North Am.
2018
,102, 13–33.
[CrossRef]
29. Nam, S.Y. Obesity-related digestive diseases and their pathophysiology. Gut Liver 2017,11, 323. [CrossRef]
30.
Catalan, V.; Aviles-Olmos, I.; Rodriguez, A.; Becerril, S.; Fernandez-Formoso, J.A.; Kiortsis, D.; Portincasa, P.; Gomez-Ambrosi,
J.; Fruhbeck, G. Time to Consider the “Exposome Hypothesis” in the Development of the Obesity Pandemic. Nutrients
2022
,
14, 1597. [CrossRef]
31.
Matsuzawa, Y. Therapy Insight: Adipocytokines in metabolic syndrome and related cardiovascular disease. Nat. Clin. Pract.
Cardiovasc. Med. 2006,3, 35–42. [CrossRef] [PubMed]
32.
Tilg, H.; Moschen, A.R. Adipocytokines: Mediators linking adipose tissue, inflammation and immunity. Nat. Rev. Immunol.
2006
,
6, 772–783. [CrossRef]
33.
Despres, J.P.; Lemieux, I.; Bergeron, J.; Pibarot, P.; Mathieu, P.; Larose, E.; Rodes-Cabau, J.; Bertrand, O.F.; Poirier, P. Abdominal
obesity and the metabolic syndrome: Contribution to global cardiometabolic risk. Arterioscler. Thromb. Vasc. Biol.
2008
,
28, 1039–1049. [CrossRef]
34.
Deschênes, D.; Couture, P.; Dupont, P.; Tchernof, A. Subdivision of the Subcutaneous Adipose Tissue Compartment and
Lipid-Lipoprotein Levels in Women. Obesity 2003,11, 469–476. [CrossRef]
35.
Abate, N.; Garg, A.; Peshock, R.M.; Stray-Gundersen, J.; Grundy, S.M. Relationships of generalized and regional adiposity to
insulin sensitivity in men. J. Clin. Investig. 1995,96, 88. [CrossRef]
36.
Vecchie, A.; Dallegri, F.; Carbone, F.; Bonaventura, A.; Liberale, L.; Portincasa, P.; Fruhbeck, G.; Montecucco, F. Obesity phenotypes
and their paradoxical association with cardiovascular diseases. Eur. J. Intern. Med. 2018,48, 6–17. [CrossRef]
37.
Gonzalez-Muniesa, P.; Martinez-Gonzalez, M.A.; Hu, F.B.; Despres, J.P.; Matsuzawa, Y.; Loos, R.J.F.; Moreno, L.A.; Bray, G.A.;
Martinez, J.A. Obesity. Nat. Rev. Dis. Primers 2017,3, 17034. [CrossRef]
38.
Aung, K.; Lorenzo, C.; Hinojosa, M.A.; Haffner, S.M. Risk of developing diabetes and cardiovascular disease in metabolically
unhealthy normal-weight and metabolically healthy obese individuals. J. Clin. Endocrinol. Metab. 2014,99, 462–468. [CrossRef]
39.
Wei, Y.; Rector, R.S.; Thyfault, J.P.; Ibdah, J.A. Nonalcoholic fatty liver disease and mitochondrial dysfunction. World J. Gastroenterol.
WJG 2008,14, 193–199. [CrossRef]
40. Sharma, A.M.; Kushner, R.F. A proposed clinical staging system for obesity. Int. J. Obes. 2009,33, 289–295. [CrossRef]
41.
Blundell, J.E.; Dulloo, A.G.; Salvador, J.; Fruhbeck, G.; BMI, E.S.W.G.o. Beyond BMI—Phenotyping the obesities. Obes. Facts
2014
,
7, 322–328. [CrossRef] [PubMed]
42.
Fruhbeck, G.; Busetto, L.; Dicker, D.; Yumuk, V.; Goossens, G.H.; Hebebrand, J.; Halford, J.G.C.; Farpour-Lambert, N.J.; Blaak,
E.E.; Woodward, E.; et al. The ABCD of Obesity: An EASO Position Statement on a Diagnostic Term with Clinical and Scientific
Implications. Obes. Facts 2019,12, 131–136. [CrossRef] [PubMed]
Nutrients 2022,14, 3112 22 of 31
43.
Mechanick, J.I.; Farkouh, M.E.; Newman, J.D.; Garvey, W.T. Cardiometabolic-Based Chronic Disease, Addressing Knowledge and
Clinical Practice Gaps: JACC State-of-the-Art Review. J. Am. Coll. Cardiol. 2020,75, 539–555. [CrossRef]
44.
Donini, L.M.; Busetto, L.; Bauer, J.M.; Bischoff, S.; Boirie, Y.; Cederholm, T.; Cruz-Jentoft, A.J.; Dicker, D.; Fruhbeck, G.;
Giustina, A.; et al.
Critical appraisal of definitions and diagnostic criteria for sarcopenic obesity based on a systematic review.
Clin. Nutr. 2020,39, 2368–2388. [CrossRef]
45.
Landecho, M.F.; Tuero, C.; Valentí, V.; Bilbao, I.; de la Higuera, M.; Frühbeck, G. Relevance of leptin and other adipokines in
obesity-associated cardiovascular risk. Nutrients 2019,11, 2664. [CrossRef] [PubMed]
46.
Cuthbertson, D.J.; Wilding, J.P.H. Metabolically healthy obesity: Time for a change of heart? Nat. Rev. Endocrinol.
2021
,
17, 519–520
.
[CrossRef] [PubMed]
47.
Guglielmetti, S.; Bernardi, S.; Del Bo, C.; Cherubini, A.; Porrini, M.; Gargari, G.; Hidalgo-Liberona, N.; Gonzalez-Dominguez,
R.; Peron, G.; Zamora-Ros, R.; et al. Effect of a polyphenol-rich dietary pattern on intestinal permeability and gut and blood
microbiomics in older subjects: Study protocol of the MaPLE randomised controlled trial. BMC Geriatr.
2020
,20, 77. [CrossRef]
[PubMed]
48.
Primeau, V.; Coderre, L.; Karelis, A.D.; Brochu, M.; Lavoie, M.E.; Messier, V.; Sladek, R.; Rabasa-Lhoret, R. Characterizing the
profile of obese patients who are metabolically healthy. Int. J. Obes. 2011,35, 971–981. [CrossRef]
49.
Chang, Y.; Ryu, S.; Suh, B.S.; Yun, K.E.; Kim, C.W.; Cho, S.I. Impact of BMI on the incidence of metabolic abnormalities in
metabolically healthy men. Int. J. Obes. 2012,36, 1187–1194. [CrossRef]
50.
Fortuno, A.; Rodriguez, A.; Gomez-Ambrosi, J.; Muniz, P.; Salvador, J.; Diez, J.; Fruhbeck, G. Leptin inhibits angiotensin II-induced
intracellular calcium increase and vasoconstriction in the rat aorta. Endocrinology 2002,143, 3555–3560. [CrossRef]
51.
Alvarez-Sola, G.; Uriarte, I.; Latasa, M.U.; Urtasun, R.; Barcena-Varela, M.; Elizalde, M.; Jimenez, M.; Rodriguez-Ortigosa,
C.M.; Corrales, F.J.; Fernandez-Barrena, M.G.; et al. Fibroblast Growth Factor 15/19 in Hepatocarcinogenesis. Dig. Dis.
2017
,
35, 158–165. [CrossRef]
52.
Gomez-Ambrosi, J.; Gallego-Escuredo, J.M.; Catalan, V.; Rodriguez, A.; Domingo, P.; Moncada, R.; Valenti, V.; Salvador, J.; Giralt,
M.; Villarroya, F.; et al. FGF19 and FGF21 serum concentrations in human obesity and type 2 diabetes behave differently after
diet- or surgically-induced weight loss. Clin. Nutr. 2017,36, 861–868. [CrossRef]
53.
Bell, J.A.; Sabia, S.; Singh-Manoux, A.; Hamer, M.; Kivimaki, M. Healthy obesity and risk of accelerated functional decline and
disability. Int. J. Obes. 2017,41, 866–872. [CrossRef] [PubMed]
54.
Rossi, A.P.; Fantin, F.; Caliari, C.; Zoico, E.; Mazzali, G.; Zanardo, M.; Bertassello, P.; Zanandrea, V.; Micciolo, R.; Zamboni, M.
Dynapenic abdominal obesity as predictor of mortality and disability worsening in older adults: A 10-year prospective study.
Clin. Nutr. 2016,35, 199–204. [CrossRef]
55.
Donini, L.M.; Busetto, L.; Bischoff, S.; Cederholm, T.; Ballesteros-Pomar, M.D.; Batsis, J.A.; Bauer, J.M.; Boirie, Y.; Cruz-Jentoft, A.J.;
Dicker, D.; et al. Definition and diagnostic criteria for sarcopenic obesity: ESPEN and EASO consensus statement. Clin. Nutr.
ESPEN 2022,41, 990–1000. [CrossRef]
56. Cauley, J.A. An Overview of Sarcopenic Obesity. J. Clin. Densitom. 2015,18, 499–505. [CrossRef]
57.
Goisser, S.; Kemmler, W.; Porzel, S.; Volkert, D.; Sieber, C.C.; Bollheimer, L.C.; Freiberger, E. Sarcopenic obesity and complex
interventions with nutrition and exercise in community-dwelling older persons—A narrative review. Clin. Interv. Aging
2015
,
10, 1267–1282. [CrossRef] [PubMed]
58.
Kim, T.N.; Choi, K.M. The implications of sarcopenia and sarcopenic obesity on cardiometabolic disease. J. Cell. Biochem.
2015
,
116, 1171–1178. [CrossRef] [PubMed]
59.
Tian, S.; Xu, Y. Association of sarcopenic obesity with the risk of all-cause mortality: A meta-analysis of prospective cohort studies.
Geriatr. Gerontol. Int. 2016,16, 155–166. [CrossRef] [PubMed]
60.
De Meyts, P.; Delzenne, N. The Brain—Gut—Microbiome Network in Metabolic Regulation and Dysregulation. Front. Endocrinol.
2021,12, 760558. [CrossRef] [PubMed]
61.
Ladabaum, U.; Mannalithara, A.; Myer, P.A.; Singh, G. Obesity, Abdominal Obesity, Physical Activity, and Caloric Intake in US
Adults: 1988 to 2010. Am. J. Med. 2014,127, 717–727.e712. [CrossRef]
62.
Collaborators, G.B.D.O.; Afshin, A.; Forouzanfar, M.H.; Reitsma, M.B.; Sur, P.; Estep, K.; Lee, A.; Marczak, L.; Mokdad, A.H.;
Moradi-Lakeh, M.; et al. Health Effects of Overweight and Obesity in 195 Countries over 25 Years. N. Engl. J. Med.
2017
,
377, 13–27. [CrossRef] [PubMed]
63.
Hales, C.M.; Carroll, M.D.; Fryar, C.D.; Ogden, C.L. Prevalence of Obesity and Severe Obesity Among Adults: United States,
2017–2018. NCHS Data Brief 2020,360, 1–8.
64.
Centers for Disease Control and Prevention. Overweight and obesity: Adult obesity facts. 2021. Available online: https:
//www.cdc.gov/obesity/data/adult.html (accessed on 28 August 2021).
65.
Alberti, K.G.; Eckel, R.H.; Grundy, S.M.; Zimmet, P.Z.; Cleeman, J.I.; Donato, K.A.; Fruchart, J.C.; James, W.P.; Loria, C.M.;
Smith, S.C., Jr.; et al. Harmonizing the metabolic syndrome: A joint interim statement of the International Diabetes Federation
Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World
Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation
2009
,
120, 1640–1645. [CrossRef] [PubMed]
66. Eckel, R.H.; Alberti, K.G.; Grundy, S.M.; Zimmet, P.Z. The metabolic syndrome. Lancet 2010,375, 181–183. [CrossRef]
Nutrients 2022,14, 3112 23 of 31
67.
Poirier, P.; Giles, T.D.; Bray, G.A.; Hong, Y.; Stern, J.S.; Pi-Sunyer, F.X.; Eckel, R.H. Obesity and cardiovascular disease: Pathophysi-
ology, evaluation, and effect of weight loss: An update of the 1997 American Heart Association Scientific Statement on Obesity
and Heart Disease from the Obesity Committee of the Council on Nutrition, Physical Activity, and Metabolism. Circulation
2006
,
113, 898–918. [CrossRef] [PubMed]
68.
Grattagliano, I.; Di Ciaula, A.; Baj, J.; Molina-Molina, E.; Shanmugam, H.; Garruti, G.; Wang, D.Q.; Portincasa, P. Protocols for
Mitochondria as the Target of Pharmacological Therapy in the Context of Nonalcoholic Fatty Liver Disease (NAFLD). Methods
Mol. Biol. 2021,2310, 201–246. [CrossRef] [PubMed]
69.
Di Ciaula, A.; Calamita, G.; Shanmugam, H.; Khalil, M.; Bonfrate, L.; Wang, D.Q.; Baffy, G.; Portincasa, P. Mitochondria Matter:
Systemic Aspects of Nonalcoholic Fatty Liver Disease (NAFLD) and Diagnostic Assessment of Liver Function by Stable Isotope
Dynamic Breath Tests. Int. J. Mol. Sci. 2021,22, 7702. [CrossRef]
70.
Grattagliano, I.; Montezinho, L.P.; Oliveira, P.J.; Fruhbeck, G.; Gomez-Ambrosi, J.; Montecucco, F.; Carbone, F.; Wieckowski,
M.R.; Wang, D.Q.; Portincasa, P. Targeting mitochondria to oppose the progression of nonalcoholic fatty liver disease. Biochem.
Pharmacol. 2019,160, 34–45. [CrossRef]
71.
Giorgi, C.; Marchi, S.; Simoes, I.C.M.; Ren, Z.; Morciano, G.; Perrone, M.; Patalas-Krawczyk, P.; Borchard, S.; Jedrak, P.;
Pierzynowska, K.; et al. Mitochondria and Reactive Oxygen Species in Aging and Age-Related Diseases. Int. Rev. Cell Mol. Biol.
2018,340, 209–344. [CrossRef]
72.
Lu, Y.; Hajifathalian, K.; Ezzati, M.; Woodward, M.; Rimm, E.B.; Danaei, G. Metabolic mediators of the effects of body-mass
index, overweight, and obesity on coronary heart disease and stroke: A pooled analysis of 97 prospective cohorts with 1.8 million
participants. Lancet 2014,383, 970–983. [CrossRef]
73.
Faienza, M.F.; Chiarito, M.; Molina-Molina, E.; Shanmugam, H.; Lammert, F.; Krawczyk, M.; D’Amato, G.; Portincasa, P.
Childhood obesity, cardiovascular and liver health: A growing epidemic with age. World J. Pediatrics WJP
2020
,16, 438–445.
[CrossRef]
74.
Faienza, M.F.; Wang, D.Q.H.; Frühbeck, G.; Garruti, G.; Portincasa, P. The dangerous link between childhood and adulthood
predictors of obesity and metabolic syndrome. Intern. Emerg. Med. 2016,11, 175–182. [CrossRef]
75.
Akil, L.; Ahmad, H.A. Relationships between obesity and cardiovascular diseases in four southern states and Colorado. J. Health
Care Poor Underserved 2011,22, 61. [CrossRef]
76.
Bhaskaran, K.; Douglas, I.; Forbes, H.; dos-Santos-Silva, I.; Leon, D.A.; Smeeth, L. Body-mass index and risk of 22 specific cancers:
A population-based cohort study of 5.24 million UK adults. Lancet 2014,384, 755–765. [CrossRef]
77.
American Heart, A.; National Heart, L.; Blood, I.; Grundy, S.M.; Cleeman, J.I.; Daniels, S.R.; Donato, K.A.; Eckel, R.H.; Franklin,
B.A.; Gordon, D.J.; et al. Diagnosis and management of the metabolic syndrome. An American Heart Association/National
Heart, Lung, and Blood Institute Scientific Statement. Executive summary. Cardiol. Rev. 2005,13, 322–327.
78.
International Diabetes Federation. The IDF Consensus Worldwide Definition of the Metabolic Syndrome. Available on-
line: https://www.idf.org/e-library/consensus-statements/60-idfconsensus-worldwide-definitionof-the-metabolic-syndrome.
html (accessed on 23 June 2022).
79.
Ford, E.S. Prevalence of the metabolic syndrome defined by the International Diabetes Federation among adults in the U.S.
Diabetes Care 2005,28, 2745–2749. [CrossRef]
80.
Beltran-Sanchez, H.; Harhay, M.O.; Harhay, M.M.; McElligott, S. Prevalence and trends of metabolic syndrome in the adult U.S.
population, 1999–2010. J. Am. Coll. Cardiol. 2013,62, 697–703. [CrossRef]
81.
Ravikiran, M.; Bhansali, A.; Ravikumar, P.; Bhansali, S.; Dutta, P.; Thakur, J.S.; Sachdeva, N.; Bhadada, S.; Walia, R. Prevalence
and risk factors of metabolic syndrome among Asian Indians: A community survey. Diabetes Res. Clin. Pract.
2010
,89, 181–188.
[CrossRef]
82.
Zuo, H.; Shi, Z.; Hu, X.; Wu, M.; Guo, Z.; Hussain, A. Prevalence of metabolic syndrome and factors associated with its
components in Chinese adults. Metab. Clin. Exp. 2009,58, 1102–1108. [CrossRef]
83.
Ford, E.S.; Giles, W.H.; Dietz, W.H. Prevalence of the metabolic syndrome among US adults: Findings from the third National
Health and Nutrition Examination Survey. JAMA 2002,287, 356–359. [CrossRef] [PubMed]
84.
Wang, H.H.; Lee, D.K.; Liu, M.; Portincasa, P.; Wang, D.Q. Novel Insights into the Pathogenesis and Management of the Metabolic
Syndrome. Pediatric Gastroenterol. Hepatol. Nutr. 2020,23, 189–230. [CrossRef]
85.
Alberti, K.G.M.M.; Zimmet, P.; Shaw, J.; IDF Epidemiology Task Force Consensus Group. The metabolic syndrome—A new
worldwide definition. Lancet 2005,366, 1059–1062. [CrossRef]
86.
Gastaldi, G.; Giacobino, J.P.; Ruiz, J. Metabolic syndrome, a mitochondrial disease? Rev. Med. Suisse
2008
,4, 1387–1388. [PubMed]
87. Beuther, D.A. Recent insight into obesity and asthma. Curr. Opin. Pulm. Med. 2010,16, 64–70. [CrossRef] [PubMed]
88.
Strazzullo, P.; Barbato, A.; Siani, A.; Cappuccio, F.P.; Versiero, M.; Schiattarella, P.; Russo, O.; Avallone, S.; della Valle, E.; Farinaro,
E. Diagnostic criteria for metabolic syndrome: A comparative analysis in an unselected sample of adult male population. Metab.
Clin. Exp. 2008,57, 355–361. [CrossRef] [PubMed]
89.
Nisoli, E.; Clementi, E.; Carruba, M.O.; Moncada, S. Defective mitochondrial biogenesis: A hallmark of the high cardiovascular
risk in the metabolic syndrome? Circ. Res. 2007,100, 795–806. [CrossRef]
90. Huang, P.L. A comprehensive definition for metabolic syndrome. Dis. Model Mech. 2009,2, 231–237. [CrossRef]
91.
Krawczyk, M.; Wang, D.Q.; Portincasa, P.; Lammert, F. Dissecting the genetic heterogeneity of gallbladder stone formation. Semin.
Liver Dis. 2011,31, 157–172. [CrossRef] [PubMed]
Nutrients 2022,14, 3112 24 of 31
92. Grundy, S.M. Cholesterol gallstones: A fellow traveler with metabolic syndrome? Am. J. Clin. Nutr. 2004,80, 1–2. [CrossRef]
93. Portincasa, P.; Moschetta, A.; Palasciano, G. Cholesterol gallstone disease. Lancet 2006,368, 230–239. [CrossRef]
94.
Wang, D.Q.H.; Portincasa, P.; Wang, H.H. Bile Formation and Pathophysiology of Gallstones. In Encyclopedia of Gastroenterology,
2nd ed.; Kujpers, E.J., Ed.; Elsevier: Amsterdam, The Netherlands; Academic Press: Oxford, UK, 2020; pp. 287–306.
95.
Portincasa, P.; Molina-Molina, E.; Garruti, G.; Wang, D.Q. Critical Care Aspects of Gallstone Disease. J. Crit. Care Med.
2019
,
5, 6–18. [CrossRef]
96.
Portincasa, P.; van Erpecum, K.J.; Di Ciaula, A.; Wang, D.Q. The physical presence of gallstone modulates ex vivo cholesterol
crystallization pathways of human bile. Gastroenterol. Rep. 2019,7, 32–41. [CrossRef] [PubMed]
97.
Di Ciaula, A.; Wang, D.Q.; Portincasa, P. Cholesterol cholelithiasis: Part of a systemic metabolic disease, prone to primary
prevention. Expert Rev. Gastroenterol. Hepatol. 2019,13, 157–171. [CrossRef]
98.
Mendez-Sanchez, N.; Bugianesi, E.; Gish, R.G.; Lammert, F.; Tilg, H.; Nguyen, M.H.; Sarin, S.K.; Fabrellas, N.; Zelber-Sagi, S.;
Fan, J.G.; et al. Global multi-stakeholder endorsement of the MAFLD definition. Lancet. Gastroenterol. Hepatol.
2022
,7, 388–390.
[CrossRef]
99. Powell, E.E.; Wong, V.W.; Rinella, M. Non-alcoholic fatty liver disease. Lancet 2021,397, 2212–2224. [CrossRef]
100.
Portincasa, P.; Bonfrate, L.; Khalil, M.; Angelis, M.; Calabrese, F.M.; D’Amato, M.; Wang, D.Q.; Di Ciaula, A. Intestinal Barrier and
Permeability in Health, Obesity and NAFLD. Biomedicines 2021,10, 83. [CrossRef] [PubMed]
101.
Di Ciaula, A.; Bonfrate, L.; Portincasa, P. The role of microbiota in nonalcoholic fatty liver disease. Eur. J. Clin. Investig.
2022
,
52, e13768. [CrossRef] [PubMed]
102.
Di Ciaula, A.; Passarella, S.; Shanmugam, H.; Noviello, M.; Bonfrate, L.; Wang, D.Q.-H.; Portincasa, P. Nonalcoholic Fatty Liver
Disease (NAFLD). Mitochondria as Players and Targets of Therapies? Int. J. Mol. Sci. 2021,22, 5375. [CrossRef]
103.
Di Ciaula, A.; Baj, J.; Garruti, G.; Celano, G.; De Angelis, M.; Wang, H.H.; Di Palo, D.M.; Bonfrate, L.; Wang, D.Q.; Portincasa, P.
Liver Steatosis, Gut-Liver Axis, Microbiome and Environmental Factors. A Never-Ending Bidirectional Cross-Talk. J. Clin. Med.
2020,9, 2648. [CrossRef]
104.
Molina-Molina, E.; Shanmugam, H.; Di Palo, D.; Grattagliano, I.; Portincasa, P. Exploring Liver Mitochondrial Function by
(13)C-Stable Isotope Breath Tests: Implications in Clinical Biochemistry. Methods Mol. Biol.
2021
,2310, 179–199. [CrossRef]
[PubMed]
105.
Baldini, F.; Fabbri, R.; Eberhagen, C.; Voci, A.; Portincasa, P.; Zischka, H.; Vergani, L. Adipocyte hypertrophy parallels alterations
of mitochondrial status in a cell model for adipose tissue dysfunction in obesity. Life Sci. 2021,265, 118812. [CrossRef]
106.
Bugger, H.; Abel, E.D. Molecular mechanisms for myocardial mitochondrial dysfunction in the metabolic syndrome. Clin. Sci.
2008,114, 195–210. [CrossRef] [PubMed]
107.
Spinelli, J.B.; Haigis, M.C. The multifaceted contributions of mitochondria to cellular metabolism. Nat. Cell Biol.
2018
,20, 745–754.
[CrossRef] [PubMed]
108.
Passarella, S.; Schurr, A.; Portincasa, P. Mitochondrial Transport in Glycolysis and Gluconeogenesis: Achievements and Perspec-
tives. Int. J. Mol. Sci. 2021,22, 2620. [CrossRef] [PubMed]
109.
Walsh, C.T.; Tu, B.P.; Tang, Y. Eight Kinetically Stable but Thermodynamically Activated Molecules that Power Cell Metabolism.
Chem. Rev. 2018,118, 1460–1494. [CrossRef] [PubMed]
110.
Sun, F.; Zhou, Q.; Pang, X.; Xu, Y.; Rao, Z. Revealing various coupling of electron transfer and proton pumping in mitochondrial
respiratory chain. Curr. Opin. Struct. Biol. 2013,23, 526–538. [CrossRef]
111.
Sazanov, L.A. A giant molecular proton pump: Structure and mechanism of respiratory complex I. Nat. Rev. Mol. Cell Biol.
2015
,
16, 375–388. [CrossRef] [PubMed]
112.
Alcazar-Fabra, M.; Navas, P.; Brea-Calvo, G. Coenzyme Q biosynthesis and its role in the respiratory chain structure. Biochim.
Biophys. Acta 2016,1857, 1073–1078. [CrossRef] [PubMed]
113.
Kuhlbrandt, W. Structure and function of mitochondrial membrane protein complexes. BMC Biol.
2015
,13, 89. [CrossRef]
[PubMed]
114.
Watt, I.N.; Montgomery, M.G.; Runswick, M.J.; Leslie, A.G.; Walker, J.E. Bioenergetic cost of making an adenosine triphosphate
molecule in animal mitochondria. Proc. Natl. Acad. Sci. USA 2010,107, 16823–16827. [CrossRef]
115. Schatz, G. Mitochondrial oxidative phosphorylation. Angew Chem. Int. Ed. Engl. 1967,6, 1035–1046. [CrossRef]
116. Brookes, P.S. Mitochondrial H(+) leak and ROS generation: An odd couple. Free Radic. Biol. Med. 2005,38, 12–23. [CrossRef]
117.
Venditti, P.; Di Stefano, L.; Di Meo, S. Mitochondrial metabolism of reactive oxygen species. Mitochondrion
2013
,13, 71–82.
[CrossRef]
118. Turrens, J.F. Mitochondrial formation of reactive oxygen species. J. Physiol. 2003,552, 335–344. [CrossRef] [PubMed]
119.
Pastor, N.; Weinstein, H.; Jamison, E.; Brenowitz, M. A detailed interpretation of OH radical footprints in a TBP-DNA complex
reveals the role of dynamics in the mechanism of sequence-specific binding. J. Mol. Biol. 2000,304, 55–68. [CrossRef] [PubMed]
120.
Chen, Y.R.; Zweier, J.L. Cardiac mitochondria and reactive oxygen species generation. Circ. Res.
2014
,114, 524–537. [CrossRef]
[PubMed]
121. Lipinski, B. Hydroxyl radical and its scavengers in health and disease. Oxid. Med. Cell Longev. 2011,2011, 809696. [CrossRef]
122.
Karnati, S.; Lüers, G.; Pfreimer, S.; Baumgart-Vogt, E. Mammalian SOD2 is exclusively located in mitochondria and not present in
peroxisomes. Histochem. Cell Biol. 2013,140, 105–117. [CrossRef]
123. Murphy, M.P. How mitochondria produce reactive oxygen species. Biochem. J. 2009,417, 1–13. [CrossRef]
Nutrients 2022,14, 3112 25 of 31
124.
Wang, B.; Van Veldhoven, P.P.; Brees, C.; Rubio, N.; Nordgren, M.; Apanasets, O.; Kunze, M.; Baes, M.; Agostinis, P.; Fransen,
M. Mitochondria are targets for peroxisome-derived oxidative stress in cultured mammalian cells. Free Radic. Biol. Med.
2013
,
65, 882–894. [CrossRef]
125.
Stowe, D.F.; Bienengraeber, M.; Camara, A.K.S. Mitochondrial Approaches to Protect Against Cardiac Ischemia and Reperfusion
Injury. Front. Physiol. 2011,2, 13. [CrossRef]
126.
Stowe, D.F.; Camara, A.K.S. Mitochondrial Reactive Oxygen Species Production in Excitable Cells: Modulators of Mitochondrial
and Cell Function. Antioxid. Redox Signal. 2009,11, 1373–1414. [CrossRef]
127.
Camara, A.K.S.; Lesnefsky, E.J.; Stowe, D.F. Potential Therapeutic Benefits of Strategies Directed to Mitochondria. Antioxid. Redox
Signal. 2010,13, 279–347. [CrossRef]
128. Storz, G.; Imlay, J.A. Oxidative stress. Curr. Opin. Microbiol. 1999,2, 188–194. [CrossRef]
129.
Bhatti, J.S.; Bhatti, G.K.; Reddy, P.H. Mitochondrial dysfunction and oxidative stress in metabolic disorders—A step towards
mitochondria based therapeutic strategies. Biochim. Biophys. Acta Mol. Basis Dis. 2017,1863, 1066–1077. [CrossRef] [PubMed]
130.
James, A.M.; Collins, Y.; Logan, A.; Murphy, M.P. Mitochondrial oxidative stress and the metabolic syndrome. Trends Endocrinol.
Metab. 2012,23, 429–434. [CrossRef]
131. Wallace, D.C. Mitochondrial genetic medicine. Nat. Genet. 2018,50, 1642–1649. [CrossRef] [PubMed]
132.
Austin, S.; St-Pierre, J. PGC1alpha and mitochondrial metabolism—Emerging concepts and relevance in ageing and neurodegen-
erative disorders. J. Cell Sci. 2012,125, 4963–4971. [CrossRef]
133.
Di, W.; Lv, J.; Jiang, S.; Lu, C.; Yang, Z.; Ma, Z.; Hu, W.; Yang, Y.; Xu, B. PGC-1: The Energetic Regulator in Cardiac Metabolism.
Curr. Issues Mol. Biol. 2018,28, 29–46. [CrossRef]
134.
Islam, H.; Edgett, B.A.; Gurd, B.J. Coordination of mitochondrial biogenesis by PGC-1alpha in human skeletal muscle: A
re-evaluation. Metab. Clin. Exp. 2018,79, 42–51. [CrossRef]
135. Jornayvaz, F.R.; Shulman, G.I. Regulation of mitochondrial biogenesis. Essays Biochem. 2010,47, 69–84. [CrossRef] [PubMed]
136.
Scarpulla, R.C.; Vega, R.B.; Kelly, D.P. Transcriptional integration of mitochondrial biogenesis. Trends Endocrinol. Metab.
2012
,
23, 459–466. [CrossRef]
137.
Barshad, G.; Marom, S.; Cohen, T.; Mishmar, D. Mitochondrial DNA Transcription and Its Regulation: An Evolutionary
Perspective. Trends Genet. 2018,34, 682–692. [CrossRef]
138.
Canto, C.; Auwerx, J. PGC-1alpha, SIRT1 and AMPK, an energy sensing network that controls energy expenditure. Curr. Opin.
Lipidol. 2009,20, 98–105. [CrossRef] [PubMed]
139.
Hardie, D.G. Minireview: The AMP-activated protein kinase cascade: The key sensor of cellular energy status. Endocrinology
2003,144, 5179–5183. [CrossRef]
140.
Kahn, B.B.; Alquier, T.; Carling, D.; Hardie, D.G. AMP-activated protein kinase: Ancient energy gauge provides clues to modern
understanding of metabolism. Cell Metab. 2005,1, 15–25. [CrossRef]
141.
Dominy, J.E., Jr.; Lee, Y.; Gerhart-Hines, Z.; Puigserver, P. Nutrient-dependent regulation of PGC-1alpha’s acetylation state and
metabolic function through the enzymatic activities of Sirt1/GCN5. Biochim. Biophys. Acta 2010,1804, 1676–1683. [CrossRef]
142.
Benton, C.R.; Wright, D.C.; Bonen, A. PGC-1alpha-mediated regulation of gene expression and metabolism: Implications for
nutrition and exercise prescriptions. Appl. Physiol. Nutr. Metab. 2008,33, 843–862. [CrossRef]
143. Bonen, A. PGC-1alpha-induced improvements in skeletal muscle metabolism and insulin sensitivity. Appl. Physiol. Nutr. Metab.
2009,34, 307–314. [CrossRef] [PubMed]
144.
Kang, C.; Li Ji, L. Role of PGC-1alpha signaling in skeletal muscle health and disease. Ann. N. Y. Acad. Sci.
2012
,1271, 110–117.
[CrossRef]
145. Wu, Z.; Boss, O. Targeting PGC-1 alpha to control energy homeostasis. Expert Opin. Targets 2007,11, 1329–1338. [CrossRef]
146.
Handschin, C.; Spiegelman, B.M. Peroxisome proliferator-activated receptor gamma coactivator 1 coactivators, energy homeosta-
sis, and metabolism. Endocr. Rev. 2006,27, 728–735. [CrossRef] [PubMed]
147.
Komen, J.C.; Thorburn, D.R. Turn up the power—Pharmacological activation of mitochondrial biogenesis in mouse models. Br. J.
Pharmacol. 2014,171, 1818–1836. [CrossRef] [PubMed]
148. Valero, T. Mitochondrial biogenesis: Pharmacological approaches. Curr. Pharm. Des. 2014,20, 5507–5509. [CrossRef]
149.
Radika, M.K.; Anuradha, C.V. Activation of insulin signaling and energy sensing network by AICAR, an AMPK activator in
insulin resistant rat tissues. J. Basic Clin. Physiol. Pharm. 2015,26, 563–574. [CrossRef]
150.
Yarnoz-Esquiroz, P.; Olazaran, L.; Aguas-Ayesa, M.; Perdomo, C.M.; Garcia-Goni, M.; Silva, C.; Fernandez-Formoso, J.A.; Escalada,
J.; Montecucco, F.; Portincasa, P.; et al. ‘Obesities’: Position statement on a complex disease entity with multifaceted drivers. Eur.
J. Clin. Investig. 2022,52, e13811. [CrossRef] [PubMed]
151.
de Mello, A.H.; Costa, A.B.; Engel, J.D.G.; Rezin, G.T. Mitochondrial dysfunction in obesity. Life Sci.
2018
,192, 26–32. [CrossRef]
[PubMed]
152.
Anderson, E.J.; Lustig, M.E.; Boyle, K.E.; Woodlief, T.L.; Kane, D.A.; Lin, C.T.; Price, J.W., 3rd; Kang, L.; Rabinovitch, P.S.; Szeto,
H.H.; et al. Mitochondrial H
2
O
2
emission and cellular redox state link excess fat intake to insulin resistance in both rodents and
humans. J. Clin. Investig. 2009,119, 573–581. [CrossRef] [PubMed]
153.
Rong, J.X.; Qiu, Y.; Hansen, M.K.; Zhu, L.; Zhang, V.; Xie, M.; Okamoto, Y.; Mattie, M.D.; Higashiyama, H.; Asano, S.; et al.
Adipose Mitochondrial Biogenesis Is Suppressed in db/db and High-Fat Diet–Fed Mice and Improved by Rosiglitazone. Diabetes
2007,56, 1751–1760. [CrossRef]
Nutrients 2022,14, 3112 26 of 31
154.
Chen, C.C.; Lee, T.Y.; Kwok, C.F.; Hsu, Y.P.; Shih, K.C.; Lin, Y.J.; Ho, L.T. Cannabinoid receptor type 1 mediates high-fat diet-
induced insulin resistance by increasing forkhead box O1 activity in a mouse model of obesity. Int. J. Mol. Med.
2016
,37, 743–754.
[CrossRef]
155.
Konopka, A.R.; Asante, A.; Lanza, I.R.; Robinson, M.M.; Johnson, M.L.; Dalla Man, C.; Cobelli, C.; Amols, M.H.; Irving, B.A.;
Nair, K.S. Defects in mitochondrial efficiency and H
2
O
2
emissions in obese women are restored to a lean phenotype with aerobic
exercise training. Diabetes 2015,64, 2104–2115. [CrossRef]
156.
Semple, R.K.; Crowley, V.C.; Sewter, C.P.; Laudes, M.; Christodoulides, C.; Considine, R.V.; Vidal-Puig, A.; O’Rahilly, S. Expression
of the thermogenic nuclear hormone receptor coactivator PGC-1alpha is reduced in the adipose tissue of morbidly obese subjects.
Int. J. Obes. Relat. Metab. Disord. J. Int. Assoc. Study Obes. 2004,28, 176–179. [CrossRef]
157.
Diogo, C.V.; Grattagliano, I.; Oliveira, P.J.; Bonfrate, L.; Portincasa, P. Re-wiring the circuit: Mitochondria as a pharmacological
target in liver disease. Curr. Med. Chem. 2011,18, 5448–5465. [CrossRef] [PubMed]
158.
Grattagliano, I.; Russmann, S.; Diogo, C.; Bonfrate, L.; Oliveira, P.J.; Wang, D.Q.; Portincasa, P. Mitochondria in chronic liver
disease. Curr. Drug Targets 2011,12, 879–893. [CrossRef] [PubMed]
159.
Caldwell, S.H.; Swerdlow, R.H.; Khan, E.M.; Iezzoni, J.C.; Hespenheide, E.E.; Parks, J.K.; Parker, W.D., Jr. Mitochondrial
abnormalities in non-alcoholic steatohepatitis. J. Hepatol. 1999,31, 430–434. [CrossRef]
160.
Szczepaniak, L.S.; Nurenberg, P.; Leonard, D.; Browning, J.D.; Reingold, J.S.; Grundy, S.; Hobbs, H.H.; Dobbins, R.L. Magnetic
resonance spectroscopy to measure hepatic triglyceride content: Prevalence of hepatic steatosis in the general population. Am. J.
Physiol. Endocrinol. Metab. 2005,288, E462–E468. [CrossRef]
161.
Simoes, I.C.M.; Karkucinska-Wieckowska, A.; Janikiewicz, J.; Szymanska, S.; Pronicki, M.; Dobrzyn, P.; Dabrowski, M.; Dobrzyn,
A.; Oliveira, P.J.; Zischka, H.; et al. Western Diet Causes Obesity-Induced Nonalcoholic Fatty Liver Disease Development by
Differentially Compromising the Autophagic Response. Antioxidants 2020,9, 995. [CrossRef]
162. Oyewole, A.O.; Birch-Machin, M.A. Mitochondria-targeted antioxidants. FASEB J. 2015,29, 4766–4771. [CrossRef]
163.
Longo, M.; Meroni, M.; Paolini, E.; Macchi, C.; Dongiovanni, P. Mitochondrial dynamics and nonalcoholic fatty liver disease
(NAFLD): New perspectives for a fairy-tale ending? Metab. Clin. Exp. 2021,117, 154708. [CrossRef]
164.
Ajaz, S.; McPhail, M.J.; Gnudi, L.; Trovato, F.M.; Mujib, S.; Napoli, S.; Carey, I.; Agarwal, K. Mitochondrial dysfunction as a
mechanistic biomarker in patients with non-alcoholic fatty liver disease (NAFLD). Mitochondrion
2021
,57, 119–130. [CrossRef]
[PubMed]
165.
Shannon, C.E.; Ragavan, M.; Palavicini, J.P.; Fourcaudot, M.; Bakewell, T.M.; Valdez, I.A.; Ayala, I.; Jin, E.S.; Madesh, M.;
Han, X.; et al.
Insulin resistance is mechanistically linked to hepatic mitochondrial remodeling in non-alcoholic fatty liver disease.
Mol. Metab. 2021,45, 101154. [CrossRef]
166.
Li, Y.; Wu, J.; Yang, M.; Wei, L.; Wu, H.; Wang, Q.; Shi, H. Physiological evidence of mitochondrial permeability transition
pore opening caused by lipid deposition leading to hepatic steatosis in db/db mice. Free Radic. Biol. Med.
2021
,162, 523–532.
[CrossRef] [PubMed]
167.
Garcia-Martinez, I.; Santoro, N.; Chen, Y.; Hoque, R.; Ouyang, X.; Caprio, S.; Shlomchik, M.J.; Coffman, R.L.; Candia, A.;
Mehal, W.Z. Hepatocyte mitochondrial DNA drives nonalcoholic steatohepatitis by activation of TLR9. J. Clin. Investig.
2016
,
126, 859–864. [CrossRef]
168.
Pan, J.; Ou, Z.; Cai, C.; Li, P.; Gong, J.; Ruan, X.Z.; He, K. Fatty acid activates NLRP3 inflammasomes in mouse Kupffer cells
through mitochondrial DNA release. Cell Immunol. 2018,332, 111–120. [CrossRef]
169.
Pirola, C.J.; Garaycoechea, M.; Flichman, D.; Castano, G.O.; Sookoian, S. Liver mitochondrial DNA damage and genetic variability
of Cytochrome b—A key component of the respirasome—Drive the severity of fatty liver disease. J. Intern. Med.
2021
,289, 84–96.
[CrossRef] [PubMed]
170.
Malik, A.N.; Czajka, A. Is mitochondrial DNA content a potential biomarker of mitochondrial dysfunction? Mitochondrion
2013
,
13, 481–492. [CrossRef] [PubMed]
171.
Zhao, R.Z.; Jiang, S.; Zhang, L.; Yu, Z.B. Mitochondrial electron transport chain, ROS generation and uncoupling. Int. J. Mol. Med.
2019,44, 3–15. [CrossRef] [PubMed]
172.
Aubert, J.; Begriche, K.; Knockaert, L.; Robin, M.A.; Fromenty, B. Increased expression of cytochrome P450 2E1 in nonalcoholic
fatty liver disease: Mechanisms and pathophysiological role. Clin. Res. Hepatol. Gastroenterol. 2011,35, 630–637. [CrossRef]
173.
Weltman, M.D.; Farrell, G.C.; Liddle, C. Increased hepatocyte CYP2E1 expression in a rat nutritional model of hepatic steatosis
with inflammation. Gastroenterology 1996,111, 1645–1653. [CrossRef]
174.
Chalasani, N.; Gorski, J.C.; Asghar, M.S.; Asghar, A.; Foresman, B.; Hall, S.D.; Crabb, D.W. Hepatic cytochrome P450 2E1 activity
in nondiabetic patients with nonalcoholic steatohepatitis. Hepatology 2003,37, 544–550. [CrossRef]
175.
Piccinin, E.; Villani, G.; Moschetta, A. Metabolic aspects in NAFLD, NASH and hepatocellular carcinoma: The role of PGC1
coactivators. Nat. Rev. Gastroenterol. Hepatol. 2019,16, 160–174. [CrossRef]
176.
Kelley, D.E.; He, J.; Menshikova, E.V.; Ritov, V.B. Dysfunction of mitochondria in human skeletal muscle in type 2 diabetes.
Diabetes 2002,51, 2944–2950. [CrossRef] [PubMed]
177.
Jezek, P.; Hlavata, L. Mitochondria in homeostasis of reactive oxygen species in cell, tissues, and organism. Int. J. Biochem. Cell
Biol. 2005,37, 2478–2503. [CrossRef] [PubMed]
178.
Antonetti, D.A.; Reynet, C.; Kahn, C.R. Increased expression of mitochondrial-encoded genes in skeletal muscle of humans with
diabetes mellitus. J. Clin. Invest. 1995,95, 1383–1388. [CrossRef]
Nutrients 2022,14, 3112 27 of 31
179.
Prasun, P. Mitochondrial dysfunction in metabolic syndrome. Biochim. Biophys. Acta Mol. Basis Dis.
2020
,1866, 165838. [CrossRef]
180.
Lahera, V.; de Las Heras, N.; López-Farré, A.; Manucha, W.; Ferder, L. Role of Mitochondrial Dysfunction in Hypertension and
Obesity. Curr. Hypertens. Rep. 2017,19, 11. [CrossRef] [PubMed]
181.
Furukawa, S.; Fujita, T.; Shimabukuro, M.; Iwaki, M.; Yamada, Y.; Nakajima, Y.; Nakayama, O.; Makishima, M.; Matsuda, M.;
Shimomura, I. Increased oxidative stress in obesity and its impact on metabolic syndrome. J. Clin. Invest.
2004
,114, 1752–1761.
[CrossRef]
182. Dikalov, S. Cross talk between mitochondria and NADPH oxidases. Free Radic. Biol. Med. 2011,51, 1289–1301. [CrossRef]
183.
Choo, H.J.; Kim, J.H.; Kwon, O.B.; Lee, C.S.; Mun, J.Y.; Han, S.S.; Yoon, Y.S.; Yoon, G.; Choi, K.M.; Ko, Y.G. Mitochondria are
impaired in the adipocytes of type 2 diabetic mice. Diabetologia 2006,49, 784–791. [CrossRef]
184.
Petersen, K.F.; Befroy, D.; Dufour, S.; Dziura, J.; Ariyan, C.; Rothman, D.L.; DiPietro, L.; Cline, G.W.; Shulman, G.I. Mitochondrial
dysfunction in the elderly: Possible role in insulin resistance. Science 2003,300, 1140–1142. [CrossRef]
185.
Lee, H.Y.; Choi, C.S.; Birkenfeld, A.L.; Alves, T.C.; Jornayvaz, F.R.; Jurczak, M.J.; Zhang, D.; Woo, D.K.; Shadel, G.S.;
Ladiges, W.; et al
. Targeted expression of catalase to mitochondria prevents age-associated reductions in mitochondrial function
and insulin resistance. Cell Metab. 2010,12, 668–674. [CrossRef]
186.
Steckhan, N.; Hohmann, C.D.; Kessler, C.; Dobos, G.; Michalsen, A.; Cramer, H. Effects of different dietary approaches on
inflammatory markers in patients with metabolic syndrome: A systematic review and meta-analysis. Nutrition
2016
,32, 338–348.
[CrossRef]
187.
Keane, D.; Kelly, S.; Healy, N.P.; McArdle, M.A.; Holohan, K.; Roche, H.M. Diet and metabolic syndrome: An overview. Curr.
Vasc. Pharmacol. 2013,11, 842–857. [CrossRef] [PubMed]
188.
Drake, I.; Sonestedt, E.; Ericson, U.; Wallström, P.; Orho-Melander, M. A Western dietary pattern is prospectively associated with
cardio-metabolic traits and incidence of the metabolic syndrome. Br. J. Nutr. 2018,119, 1168–1176. [CrossRef] [PubMed]
189.
Marrone, G.; Guerriero, C.; Palazzetti, D.; Lido, P.; Marolla, A.; Di Daniele, F.; Noce, A. Vegan Diet Health Benefits in Metabolic
Syndrome. Nutrients 2021,13, 817. [CrossRef]
190.
Martinez, K.B.; Leone, V.; Chang, E.B. Western diets, gut dysbiosis, and metabolic diseases: Are they linked? Gut Microbes
2017
,
8, 130–142. [CrossRef] [PubMed]
191.
Mirmiran, P.; Bahadoran, Z.; Vakili, A.Z.; Azizi, F. Western dietary pattern increases risk of cardiovascular disease in Iranian
adults: A prospective population-based study. Appl. Physiol. Nutr. Metab. 2017,42, 326–332. [CrossRef] [PubMed]
192.
Turner-McGrievy, G.; Harris, M. Key elements of plant-based diets associated with reduced risk of metabolic syndrome. Curr.
Diabetes Rep. 2014,14, 524. [CrossRef] [PubMed]
193.
Shah, B.; Newman, J.D.; Woolf, K.; Ganguzza, L.; Guo, Y.; Allen, N.; Zhong, J.; Fisher, E.A.; Slater, J. Anti-Inflammatory Effects of
a Vegan Diet Versus the American Heart Association-Recommended Diet in Coronary Artery Disease Trial. J. Am. Heart Assoc.
2018,7, e011367. [CrossRef]
194. Magriplis, E.; Chourdakis, M. Special Issue “Mediterranean Diet and Metabolic Diseases”. Nutrients 2021,13, 2680. [CrossRef]
195.
D’Innocenzo, S.; Biagi, C.; Lanari, M. Obesity and the Mediterranean Diet: A Review of Evidence of the Role and Sustainability of
the Mediterranean Diet. Nutrients 2019,11, 1306. [CrossRef]
196.
Carbone, F.; Ciaula, A.D.; Pagano, S.; Minetti, S.; Ansaldo, A.M.; Ferrara, D.; Belfiore, A.; Elia, E.; Pugliese, S.;
Ostilio Palmieri, V.; et al
.
Anti-ApoA-1 IgGs predict resistance to waist circumference reduction after Mediterranean diet. Eur. J. Clin. Invest.
2021
,
51, e13410. [CrossRef]
197.
Finicelli, M.; Squillaro, T.; Di Cristo, F.; Di Salle, A.; Melone, M.A.B.; Galderisi, U.; Peluso, G. Metabolic syndrome, Mediterranean
diet, and polyphenols: Evidence and perspectives. J. Cell. Physiol. 2019,234, 5807–5826. [CrossRef] [PubMed]
198.
Velázquez-López, L.; Santiago-Díaz, G.; Nava-Hernández, J.; Muñoz-Torres, A.V.; Medina-Bravo, P.; Torres-Tamayo, M.
Mediterranean-style diet reduces metabolic syndrome components in obese children and adolescents with obesity. BMC
Pediatrics 2014,14, 175. [CrossRef]
199.
Sayon-Orea, C.; Razquin, C.; Bullo, M.; Corella, D.; Fito, M.; Romaguera, D.; Vioque, J.; Alonso-Gomez, A.M.; Warnberg, J.;
Martinez, J.A.; et al. Effect of a Nutritional and Behavioral Intervention on Energy-Reduced Mediterranean Diet Adherence
Among Patients with Metabolic Syndrome: Interim Analysis of the PREDIMED-Plus Randomized Clinical Trial. JAMA
2019
,322,
1486–1499. [CrossRef]
200.
Bach-Faig, A.; Berry, E.M.; Lairon, D.; Reguant, J.; Trichopoulou, A.; Dernini, S.; Medina, F.X.; Battino, M.; Belahsen, R.;
Miranda, G.; et al
. Mediterranean diet pyramid today. Science and cultural updates. Public Health Nutr.
2011
,14, 2274–2284.
[CrossRef] [PubMed]
201.
Willett, W.C.; Sacks, F.; Trichopoulou, A.; Drescher, G.; Ferro-Luzzi, A.; Helsing, E.; Trichopoulos, D. Mediterranean diet pyramid:
A cultural model for healthy eating. Am. J. Clin. Nutr. 1995,61, 1402S–1406S. [CrossRef]
202.
Evert, A.B.; Boucher, J.L.; Cypress, M.; Dunbar, S.A.; Franz, M.J.; Mayer-Davis, E.J.; Neumiller, J.J.; Nwankwo, R.; Verdi,
C.L.; Urbanski, P.; et al. Nutrition therapy recommendations for the management of adults with diabetes. Diabetes Care
2014
,
37 (Suppl. S1), S120–S143. [CrossRef]
203.
Portincasa, P.; Wang, D.Q.H. Il valore di una dieta “prudente” nell’individuo adulto. Considerazioni per vivere meglio e forse
piu’ a lungo. In Atti e Relazioni Accademia Pugliese delle Scienze; Adda Editrice: Bari, Italy, 2022; Volume LVII, pp. 85–108.
204.
Fung, T.T.; Rexrode, K.M.; Mantzoros, C.S.; Manson, J.E.; Willett, W.C.; Hu, F.B. Mediterranean diet and incidence of and mortality
from coronary heart disease and stroke in women. Circulation 2009,119, 1093–1100. [CrossRef]
Nutrients 2022,14, 3112 28 of 31
205.
Gao, X.; Chen, H.; Fung, T.T.; Logroscino, G.; Schwarzschild, M.A.; Hu, F.B.; Ascherio, A. Prospective study of dietary pattern and
risk of Parkinson disease. Am. J. Clin. Nutr. 2007,86, 1486–1494. [CrossRef]
206.
Scarmeas, N.; Luchsinger, J.A.; Schupf, N.; Brickman, A.M.; Cosentino, S.; Tang, M.X.; Stern, Y. Physical activity, diet, and risk of
Alzheimer disease. JAMA 2009,302, 627–637. [CrossRef]
207.
Buckland, G.; Agudo, A.; Lujan, L.; Jakszyn, P.; Bueno-de-Mesquita, H.B.; Palli, D.; Boeing, H.; Carneiro, F.; Krogh, V.;
Sacerdote, C.; et al
. Adherence to a Mediterranean diet and risk of gastric adenocarcinoma within the European Prospective
Investigation into Cancer and Nutrition (EPIC) cohort study. Am. J. Clin. Nutr. 2010,91, 381–390. [CrossRef] [PubMed]
208.
Buckland, G.; Travier, N.; Cottet, V.; Gonzalez, C.A.; Lujan-Barroso, L.; Agudo, A.; Trichopoulou, A.; Lagiou, P.; Trichopoulos, D.;
Peeters, P.H.; et al. Adherence to the mediterranean diet and risk of breast cancer in the European prospective investigation into
cancer and nutrition cohort study. Int. J. Cancer 2013,132, 2918–2927. [CrossRef]
209.
La Vecchia, C. Association between Mediterranean dietary patterns and cancer risk. Nutr. Rev.
2009
,67 (Suppl. S1), S126–S129.
[CrossRef]
210.
Panagiotakos, D.B.; Polystipioti, A.; Papairakleous, N.; Polychronopoulos, E. Long-term adoption of a Mediterranean diet
is associated with a better health status in elderly people; a cross-sectional survey in Cyprus. Asia Pac. J. Clin. Nutr.
2007
,
16, 331–337.
211.
Nunez-Cordoba, J.M.; Valencia-Serrano, F.; Toledo, E.; Alonso, A.; Martinez-Gonzalez, M.A. The Mediterranean diet and incidence
of hypertension: The Seguimiento Universidad de Navarra (SUN) Study. Am. J. Epidemiol. 2009,169, 339–346. [CrossRef]
212.
Martinez-Gonzalez, M.A.; de la Fuente-Arrillaga, C.; Nunez-Cordoba, J.M.; Basterra-Gortari, F.J.; Beunza, J.J.; Vazquez, Z.; Benito,
S.; Tortosa, A.; Bes-Rastrollo, M. Adherence to Mediterranean diet and risk of developing diabetes: Prospective cohort study. BMJ
2008,336, 1348–1351. [CrossRef]
213.
Schroder, H.; Marrugat, J.; Vila, J.; Covas, M.I.; Elosua, R. Adherence to the traditional mediterranean diet is inversely associated
with body mass index and obesity in a spanish population. J. Nutr. 2004,134, 3355–3361. [CrossRef] [PubMed]
214. Tektonidis, T.G.; Akesson, A.; Gigante, B.; Wolk, A.; Larsson, S.C. A Mediterranean diet and risk of myocardial infarction, heart
failure and stroke: A population-based cohort study. Atherosclerosis 2015,243, 93–98. [CrossRef] [PubMed]
215.
Lopez-Garcia, E.; Rodriguez-Artalejo, F.; Li, T.Y.; Fung, T.T.; Li, S.; Willett, W.C.; Rimm, E.B.; Hu, F.B. The Mediterranean-style
dietary pattern and mortality among men and women with cardiovascular disease. Am. J. Clin. Nutr.
2014
,99, 172–180. [CrossRef]
216.
Fox, C.S.; Golden, S.H.; Anderson, C.; Bray, G.A.; Burke, L.E.; de Boer, I.H.; Deedwania, P.; Eckel, R.H.; Ershow, A.G.;
Fradkin, J.; et al
. Update on Prevention of Cardiovascular Disease in Adults with Type 2 Diabetes Mellitus in Light of Re-
cent Evidence: A Scientific Statement from the American Heart Association and the American Diabetes Association. Diabetes Care
2015,38, 1777–1803. [CrossRef]
217.
Zito, F.P.; Polese, B.; Vozzella, L.; Gala, A.; Genovese, D.; Verlezza, V.; Medugno, F.; Santini, A.; Barrea, L.; Cargiolli, M.; et al.
Good adherence to mediterranean diet can prevent gastrointestinal symptoms: A survey from Southern Italy. World J. Gastrointest.
Pharm. 2016,7, 564–571. [CrossRef]
218.
Khalil, M.; Hayek, S.; Khalil, N.; Serale, N.; Vergani, L.; Calasso, M.; De Angelis, M.; Portincasa, P. Role of Sumac (Rhus coriaria L.)
in the management of metabolic syndrome and related disorders: Focus on NAFLD-atherosclerosis interplay. J. Funct. Foods
2021
,
87, 104811. [CrossRef]
219.
Khalil, M.; Rita Caponio, G.; Diab, F.; Shanmugam, H.; Di Ciaula, A.; Khalifeh, H.; Vergani, L.; Calasso, M.; De Angelis, M.;
Portincasa, P. Unraveling the beneficial effects of herbal Lebanese mixture “Za’atar”. History, studies, and properties of a potential
healthy food ingredient. J. Funct. Foods 2022,90, 104993. [CrossRef]
220.
Khalil, M.; Khalifeh, H.; Baldini, F.; Serale, N.; Parodi, A.; Voci, A.; Vergani, L.; Daher, A. Antitumor Activity of Ethanolic
Extract from Thymbra Spicata L. aerial Parts: Effects on Cell Viability and Proliferation, Apoptosis Induction, STAT3, and NF-kB
Signaling. Nutr. Cancer 2021,73, 1193–1206. [CrossRef]
221.
Khalil, M.; Bazzi, A.; Zeineddine, D.; Jomaa, W.; Daher, A.; Awada, R. Repressive effect of Rhus coriaria L. fruit extracts on
microglial cells-mediated inflammatory and oxidative stress responses. J. Ethnopharmacol. 2021,269, 113748. [CrossRef]
222.
Farooqui, A.A.; Farooqui, T.; Panza, F.; Frisardi, V. Metabolic syndrome as a risk factor for neurological disorders. Cell. Mol. Life
Sci. CMLS 2012,69, 741–762. [CrossRef]
223.
Fernandez-Sanchez, A.; Madrigal-Santillan, E.; Bautista, M.; Esquivel-Soto, J.; Morales-Gonzalez, A.; Esquivel-Chirino, C.;
Durante-Montiel, I.; Sanchez-Rivera, G.; Valadez-Vega, C.; Morales-Gonzalez, J.A. Inflammation, oxidative stress, and obesity. Int.
J. Mol. Sci. 2011,12, 3117–3132. [CrossRef]
224.
Freeman, B.A.; Baker, P.R.; Schopfer, F.J.; Woodcock, S.R.; Napolitano, A.; d’Ischia, M. Nitro-fatty acid formation and signaling. J.
Biol. Chem. 2008,283, 15515–15519. [CrossRef]
225. Farooqui, A.A. Phytochemicals, Signal Transduction, and Neurological Disorders; Springer: New York, NY, USA, 2012.
226.
Calder, P.C. Polyunsaturated fatty acids and inflammatory processes: New twists in an old tale. Biochimie
2009
,91, 791–795.
[CrossRef]
227.
Lagouge, M.; Argmann, C.; Gerhart-Hines, Z.; Meziane, H.; Lerin, C.; Daussin, F.; Messadeq, N.; Milne, J.; Lambert, P.;
Elliott, P.; et al
. Resveratrol improves mitochondrial function and protects against metabolic disease by activating SIRT1 and
PGC-1alpha. Cell 2006,127, 1109–1122. [CrossRef]
228.
Hardie, D.G.; Ross, F.A.; Hawley, S.A. AMPK: A nutrient and energy sensor that maintains energy homeostasis. Nat. Rev. Mol.
Cell Biol. 2012,13, 251–262. [CrossRef]
Nutrients 2022,14, 3112 29 of 31
229.
Scarmeas, N.; Stern, Y.; Mayeux, R.; Luchsinger, J.A. Mediterranean diet, Alzheimer disease, and vascular mediation. Arch. Neurol.
2006,63, 1709–1717. [CrossRef] [PubMed]
230.
Castro-Quezada, I.; Roman-Vinas, B.; Serra-Majem, L. The Mediterranean diet and nutritional adequacy: A review. Nutrients
2014,6, 231–248. [CrossRef] [PubMed]
231.
Wang, J.; Persuitte, G.; Olendzki, B.C.; Wedick, N.M.; Zhang, Z.; Merriam, P.A.; Fang, H.; Carmody, J.; Olendzki, G.F.; Ma, Y.
Dietary magnesium intake improves insulin resistance among non-diabetic individuals with metabolic syndrome participating in
a dietary trial. Nutrients 2013,5, 3910–3919. [CrossRef]
232.
Lu, J.; Gu, Y.; Guo, M.; Chen, P.; Wang, H.; Yu, X. Serum Magnesium Concentration Is Inversely Associated with Albuminuria
and Retinopathy among Patients with Diabetes. J. Diabetes Res. 2016,2016, 1260141. [CrossRef]
233.
Paletas, K.; Athanasiadou, E.; Sarigianni, M.; Paschos, P.; Kalogirou, A.; Hassapidou, M.; Tsapas, A. The protective role of the
Mediterranean diet on the prevalence of metabolic syndrome in a population of Greek obese subjects. J. Am. Coll. Nutr.
2010
,
29, 41–45. [CrossRef]
234.
Dominguez, L.J.; Di Bella, G.; Veronese, N.; Barbagallo, M. Impact of Mediterranean Diet on Chronic Non-Communicable
Diseases and Longevity. Nutrients 2021,13, 2028. [CrossRef]
235.
Farooqui, A.A. Essential Fatty Acid Metabolism in Metabolic Syndrome and Neurological Disorders. In Metabolic Syndrome;
Springer: New York, NY, USA, 2013; pp. 67–101.
236.
Chrysohoou, C.; Panagiotakos, D.B.; Pitsavos, C.; Das, U.N.; Stefanadis, C. Adherence to the Mediterranean diet attenuates
inflammation and coagulation process in healthy adults: The ATTICA Study. J. Am. Coll. Cardiol. 2004,44, 152–158. [CrossRef]
237.
Richard, C.; Couture, P.; Desroches, S.; Lamarche, B. Effect of the Mediterranean diet with and without weight loss on markers of
inflammation in men with metabolic syndrome. Obesity 2013,21, 51–57. [CrossRef] [PubMed]
238.
Georgousopoulou, E.N.; Kastorini, C.M.; Milionis, H.J.; Ntziou, E.; Kostapanos, M.S.; Nikolaou, V.; Vemmos, K.N.; Goudevenos,
J.A.; Panagiotakos, D.B. Association between mediterranean diet and non-fatal cardiovascular events, in the context of anxiety
and depression disorders: A case/case-control study. Hell. J. Cardiol. 2014,55, 24–31.
239.
Couto, E.; Boffetta, P.; Lagiou, P.; Ferrari, P.; Buckland, G.; Overvad, K.; Dahm, C.C.; Tjonneland, A.; Olsen, A.;
Clavel-Chapelon, F.; et al
. Mediterranean dietary pattern and cancer risk in the EPIC cohort. Br. J. Cancer
2011
,104,
1493–1499. [CrossRef]
240.
Salas-Salvado, J.; Bullo, M.; Estruch, R.; Ros, E.; Covas, M.I.; Ibarrola-Jurado, N.; Corella, D.; Aros, F.; Gomez-Gracia, E.; Ruiz-
Gutierrez, V.; et al. Prevention of diabetes with Mediterranean diets: A subgroup analysis of a randomized trial. Ann. Intern. Med.
2014,160, 1–10. [CrossRef] [PubMed]
241.
Salamone, F.; Li Volti, G.; Titta, L.; Puzzo, L.; Barbagallo, I.; La Delia, F.; Zelber-Sagi, S.; Malaguarnera, M.; Pelicci, P.G.;
Giorgio, M.; et al. Moro orange juice prevents fatty liver in mice. World J. Gastroenterol. 2012,18, 3862–3868. [CrossRef]
242.
Garcia-Marcos, L.; Castro-Rodriguez, J.A.; Weinmayr, G.; Panagiotakos, D.B.; Priftis, K.N.; Nagel, G. Influence of Mediterranean
diet on asthma in children: A systematic review and meta-analysis. Pediatr. Allergy Immunol. 2013,24, 330–338. [CrossRef]
243.
Salas-Salvado, J.; Bullo, M.; Babio, N.; Martinez-Gonzalez, M.A.; Ibarrola-Jurado, N.; Basora, J.; Estruch, R.; Covas, M.I.; Corella,
D.; Aros, F.; et al. Reduction in the incidence of type 2 diabetes with the Mediterranean diet: Results of the PREDIMED-Reus
nutrition intervention randomized trial. Diabetes Care 2011,34, 14–19. [CrossRef] [PubMed]
244.
Wong, C.Y.; Yiu, K.H.; Li, S.W.; Lee, S.; Tam, S.; Lau, C.P.; Tse, H.F. Fish-oil supplement has neutral effects on vascular and
metabolic function but improves renal function in patients with Type 2 diabetes mellitus. Diabet Med.
2010
,27, 54–60. [CrossRef]
245.
Seidl, S.E.; Santiago, J.A.; Bilyk, H.; Potashkin, J.A. The emerging role of nutrition in Parkinson’s disease. Front Aging Neurosci
2014,6, 36. [CrossRef] [PubMed]
246.
Martinez-Gonzalez, M.A.; Bes-Rastrollo, M.; Serra-Majem, L.; Lairon, D.; Estruch, R.; Trichopoulou, A. Mediterranean food
pattern and the primary prevention of chronic disease: Recent developments. Nutr. Rev.
2009
,67 (Suppl. S1), S111–S116.
[CrossRef]
247.
Sofi, F.; Cesari, F.; Abbate, R.; Gensini, G.F.; Casini, A. Adherence to Mediterranean diet and health status: Meta-analysis. BMJ
2008,337, a1344. [CrossRef]
248.
Tsai, K.L.; Hung, C.H.; Chan, S.H.; Hsieh, P.L.; Ou, H.C.; Cheng, Y.H.; Chu, P.M. Chlorogenic Acid Protects Against oxLDL-
Induced Oxidative Damage and Mitochondrial Dysfunction by Modulating SIRT1 in Endothelial Cells. Mol. Nutr. Food Res.
2018
,
62, e1700928. [CrossRef] [PubMed]
249.
Duluc, L.; Jacques, C.; Soleti, R.; Andriantsitohaina, R.; Simard, G. Delphinidin inhibits VEGF induced-mitochondrial biogenesis
and Akt activation in endothelial cells. Int. J. Biochem. Cell Biol. 2014,53, 9–14. [CrossRef]
250.
Wang, J.; Zou, Q.; Suo, Y.; Tan, X.; Yuan, T.; Liu, Z.; Liu, X. Lycopene ameliorates systemic inflammation-induced synaptic
dysfunction via improving insulin resistance and mitochondrial dysfunction in the liver-brain axis. Food Funct.
2019
,10, 2125–2137.
[CrossRef]
251.
Feng, C.; Luo, T.; Zhang, S.; Liu, K.; Zhang, Y.; Luo, Y.; Ge, P. Lycopene protects human SHSY5Y neuroblastoma cells against
hydrogen peroxideinduced death via inhibition of oxidative stress and mitochondriaassociated apoptotic pathways. Mol. Med.
Rep. 2016,13, 4205–4214. [CrossRef]
252.
Liu, J.; Wang, Y.; Hao, Y.; Wang, Z.; Yang, Z.; Wang, Z.; Wang, J. 5-Heptadecylresorcinol attenuates oxidative damage and
mitochondria-mediated apoptosis through activation of the SIRT3/FOXO3a signaling pathway in neurocytes. Food Funct. 2020,
11, 2535–2542. [CrossRef] [PubMed]
Nutrients 2022,14, 3112 30 of 31
253.
Gueguen, N.; Desquiret-Dumas, V.; Leman, G.; Chupin, S.; Baron, S.; Nivet-Antoine, V.; Vessieres, E.; Ayer, A.; Henrion, D.;
Lenaers, G.; et al. Resveratrol Directly Binds to Mitochondrial Complex I and Increases Oxidative Stress in Brain Mitochondria of
Aged Mice. PLoS ONE 2015,10, e0144290. [CrossRef]
254.
Baur, J.A.; Pearson, K.J.; Price, N.L.; Jamieson, H.A.; Lerin, C.; Kalra, A.; Prabhu, V.V.; Allard, J.S.; Lopez-Lluch, G.; Lewis, K.; et al.
Resveratrol improves health and survival of mice on a high-calorie diet. Nature 2006,444, 337–342. [CrossRef]
255.
Gao, Z.; Yin, J.; Zhang, J.; Ward, R.E.; Martin, R.J.; Lefevre, M.; Cefalu, W.T.; Ye, J. Butyrate improves insulin sensitivity and
increases energy expenditure in mice. Diabetes 2009,58, 1509–1517. [CrossRef]
256.
Mollica, M.P.; Mattace Raso, G.; Cavaliere, G.; Trinchese, G.; De Filippo, C.; Aceto, S.; Prisco, M.; Pirozzi, C.; Di Guida, F.;
Lama, A.; et al
. Butyrate Regulates Liver Mitochondrial Function, Efficiency, and Dynamics in Insulin-Resistant Obese Mice.
Diabetes 2017,66, 1405–1418. [CrossRef]
257.
Deng, X.; Zhang, S.; Wu, J.; Sun, X.; Shen, Z.; Dong, J.; Huang, J. Promotion of Mitochondrial Biogenesis via Activation of
AMPK-PGC1a Signaling Pathway by Ginger (Zingiber officinale Roscoe) Extract, and Its Major Active Component 6-Gingerol. J.
Food Sci. 2019,84, 2101–2111. [CrossRef] [PubMed]
258.
Perez-Ternero, C.; Werner, C.M.; Nickel, A.G.; Herrera, M.D.; Motilva, M.J.; Bohm, M.; Alvarez de Sotomayor, M.; Laufs, U.
Ferulic acid, a bioactive component of rice bran, improves oxidative stress and mitochondrial biogenesis and dynamics in mice
and in human mononuclear cells. J. Nutr. Biochem. 2017,48, 51–61. [CrossRef] [PubMed]
259.
Liu, R.; Chen, L.; Wang, Y.; Zhang, G.; Cheng, Y.; Feng, Z.; Bai, X.; Liu, J. High ratio of omega-3/omega-6 polyunsaturated fatty
acids targets mTORC1 to prevent high-fat diet-induced metabolic syndrome and mitochondrial dysfunction in mice. J. Nutr.
Biochem. 2020,79, 108330. [CrossRef]
260.
Sanchez-Calvo, B.; Cassina, A.; Mastrogiovanni, M.; Santos, M.; Trias, E.; Kelley, E.E.; Rubbo, H.; Trostchansky, A. Olive
oil-derived nitro-fatty acids: Protection of mitochondrial function in non-alcoholic fatty liver disease. J. Nutr. Biochem.
2021
,
94, 108646. [CrossRef]
261.
Cao, K.; Xu, J.; Zou, X.; Li, Y.; Chen, C.; Zheng, A.; Li, H.; Li, H.; Szeto, I.M.; Shi, Y.; et al. Hydroxytyrosol prevents diet-induced
metabolic syndrome and attenuates mitochondrial abnormalities in obese mice. Free Radic. Biol. Med.
2014
,67, 396–407. [CrossRef]
262.
Dong, Y.Z.; Li, L.; Espe, M.; Lu, K.L.; Rahimnejad, S. Hydroxytyrosol Attenuates Hepatic Fat Accumulation via Activating
Mitochondrial Biogenesis and Autophagy through the AMPK Pathway. J. Agric. Food Chem. 2020,68, 9377–9386. [CrossRef]
263.
Keshtzar, E.; Khodayar, M.J.; Javadipour, M.; Ghaffari, M.A.; Bolduc, D.L.; Rezaei, M. Ellagic acid protects against arsenic toxicity
in isolated rat mitochondria possibly through the maintaining of complex II. Hum. Exp. Toxicol. 2016,35, 1060–1072. [CrossRef]
264.
Zamani, F.; Samiei, F.; Mousavi, Z.; Azari, M.R.; Seydi, E.; Pourahmad, J. Apigenin ameliorates oxidative stress and mitochondrial
damage induced by multiwall carbon nanotubes in rat kidney mitochondria. J. Biochem. Mol. Toxicol. 2021,35, 1–7. [CrossRef]
265.
Wang, D.; Yang, Y.; Zou, X.; Zhang, J.; Zheng, Z.; Wang, Z. Antioxidant Apigenin Relieves Age-Related Muscle Atrophy by
Inhibiting Oxidative Stress and Hyperactive Mitophagy and Apoptosis in Skeletal Muscle of Mice. J. Gerontol. A Biol. Sci. Med.
Sci. 2020,75, 2081–2088. [CrossRef]
266.
Daussin, F.N.; Cuillerier, A.; Touron, J.; Bensaid, S.; Melo, B.; Al Rewashdy, A.; Vasam, G.; Menzies, K.J.; Harper, M.E.;
Heyman, E.; et al
. Dietary Cocoa Flavanols Enhance Mitochondrial Function in Skeletal Muscle and Modify Whole-Body
Metabolism in Healthy Mice. Nutrients 2021,13, 3466. [CrossRef]
267.
Okada, L.; Oliveira, C.P.; Stefano, J.T.; Nogueira, M.A.; Silva, I.; Cordeiro, F.B.; Alves, V.A.F.; Torrinhas, R.S.; Carrilho, F.J.;
Puri, P.; et al
. Omega-3 PUFA modulate lipogenesis, ER stress, and mitochondrial dysfunction markers in NASH—Proteomic and
lipidomic insight. Clin. Nutr. 2018,37, 1474–1484. [CrossRef]
268.
Anderson, E.J.; Thayne, K.A.; Harris, M.; Shaikh, S.R.; Darden, T.M.; Lark, D.S.; Williams, J.M.; Chitwood, W.R.; Kypson, A.P.;
Rodriguez, E. Do fish oil omega-3 fatty acids enhance antioxidant capacity and mitochondrial fatty acid oxidation in human atrial
myocardium via PPARgamma activation? Antioxid. Redox Signal 2014,21, 1156–1163. [CrossRef] [PubMed]
269. Yoshino, J.; Smith, G.I.; Kelly, S.C.; Julliand, S.; Reeds, D.N.; Mittendorfer, B. Effect of dietary n-3 PUFA supplementation on the
muscle transcriptome in older adults. Physiol. Rep. 2016,4, e12785. [CrossRef] [PubMed]
270.
Capo, X.; Martorell, M.; Sureda, A.; Llompart, I.; Tur, J.A.; Pons, A. Diet supplementation with DHA-enriched food in football
players during training season enhances the mitochondrial antioxidant capabilities in blood mononuclear cells. Eur. J. Nutr.
2015
,
54, 35–49. [CrossRef] [PubMed]
271.
de Ligt, M.; Bruls, Y.M.H.; Hansen, J.; Habets, M.F.; Havekes, B.; Nascimento, E.B.M.; Moonen-Kornips, E.; Schaart, G.; Schrauwen-
Hinderling, V.B.; van Marken Lichtenbelt, W.; et al. Resveratrol improves ex vivo mitochondrial function but does not affect
insulin sensitivity or brown adipose tissue in first degree relatives of patients with type 2 diabetes. Mol. Metab.
2018
,12, 39–47.
[CrossRef]
272.
Pollack, R.M.; Barzilai, N.; Anghel, V.; Kulkarni, A.S.; Golden, A.; O’Broin, P.; Sinclair, D.A.; Bonkowski, M.S.; Coleville, A.J.;
Powell, D.; et al. Resveratrol Improves Vascular Function and Mitochondrial Number but Not Glucose Metabolism in Older
Adults. J. Gerontol. A Biol. Sci. Med. Sci. 2017,72, 1703–1709. [CrossRef] [PubMed]
273.
Most, J.; Timmers, S.; Warnke, I.; Jocken, J.W.; van Boekschoten, M.; de Groot, P.; Bendik, I.; Schrauwen, P.; Goossens, G.H.; Blaak,
E.E. Combined epigallocatechin-3-gallate and resveratrol supplementation for 12 wk increases mitochondrial capacity and fat
oxidation, but not insulin sensitivity, in obese humans: A randomized controlled trial. Am. J. Clin. Nutr.
2016
,104, 215–227.
[CrossRef] [PubMed]
Nutrients 2022,14, 3112 31 of 31
274.
Joy, J.M.; Vogel, R.M.; Moon, J.R.; Falcone, P.H.; Mosman, M.M.; Pietrzkowski, Z.; Reyes, T.; Kim, M.P. Ancient peat and apple
extracts supplementation may improve strength and power adaptations in resistance trained men. BMC Complement Altern. Med.
2016,16, 224. [CrossRef]
275.
Srinivasan, S.; Guha, M.; Kashina, A.; Avadhani, N.G. Mitochondrial dysfunction and mitochondrial dynamics-The cancer
connection. Biochim. Biophys. Acta Bioenerg. 2017,1858, 602–614. [CrossRef] [PubMed]
276.
Portincasa, P.; Bonfrate, L.; Vacca, M.; De Angelis, M.; Farella, I.; Lanza, E.; Khalil, M.; Wang, D.Q.; Sperandio, M.; Di Ciaula, A.
Gut Microbiota and Short Chain Fatty Acids: Implications in Glucose Homeostasis. Int. J. Mol. Sci.
2022
,23, 1105. [CrossRef]
[PubMed]
277.
Nadtochiy, S.M.; Redman, E.K. Mediterranean diet and cardioprotection: The role of nitrite, polyunsaturated fatty acids, and
polyphenols. Nutrition 2011,27, 733–744. [CrossRef] [PubMed]
278.
Stanley, W.C.; Khairallah, R.J.; Dabkowski, E.R. Update on lipids and mitochondrial function: Impact of dietary n-3 polyunsatu-
rated fatty acids. Curr. Opin. Clin. Nutr. Metab. Care 2012,15, 122–126. [CrossRef] [PubMed]
... In contrast, the Mediterranean diet, renowned for its abundance of n-3 fatty acids, MUFAs, fiber, and essential nutrients, has been associated with enhanced longevity, cardiometabolic health benefits, and potent anti-inflammatory and antioxidant properties. 55,56 Moreover, SFAs have been implicated in compromising mitochondrial function, whereas PUFAs appear to counteract the detrimental effects of SFAs ( Figure 2B). 23,57 ...
Article
Adipose tissue serves as a dynamic endocrine organ that is pivotal in metabolic regulation. Augmenting mitochondrial activity within this tissue holds promise in combating obesity. Mitochondrial function is intricately modulated by diverse fatty acid compositions. This comprehensive review aimed to elucidate the molecular mechanisms underlying mitochondrial dysfunction induced by various fatty acid profiles. While saturated fatty acids (SFAs) pose a threat to mitochondrial integrity, polyunsaturated fatty acids (PUFAs), notably n-3, mitigate SFA-induced damage, concurrently regulating thermogenic gene expression. With regard to monounsaturated fatty acids (MUFAs), their impact on mitochondrial function in adipose tissue remains relatively unexplored. Although human studies are imperative for comprehensive insights, prioritizing the consumption of n-3 fatty acids and MUFAs has emerged as a strategic approach, potentially enhancing mitochondrial biogenesis and metabolic pathways. This synthesis underscores the critical need for further investigation of the differential effects of fatty acid types on adipose tissue mitochondria, offering potential avenues for obesity intervention.
... This correlation between the DII and a healthy diet was also detected in a research by Vahid et al. [50], which supports our findings related to food groups such as vegetables, fruits, and non-caloric beverages. Therefore, a high compliance to DII, which involves consuming a high amount of vegetables and fruits, ensures a high intake of vitamins C, E, and fiber [56]. Additionally, consuming nuts leads to an increased intake of potassium, magnesium, calcium, MUFA, PUFA, and vitamin E [57,58]. ...
Article
Full-text available
Background The metabolic syndrome (MetS) comprises metabolic irregularities, including hypertension and central obesity, which are influenced by genetic, metabolic, environmental, and dietary factors. As diet and lifestyle are risk factors for MetS, it is important to know which diet quality index better predicts MetS. The aim of this study is to compare the ability of different diet quality indices in predicting MetS and to identify the most effective one. Methods This cross-sectional study involved 5,206 participants aged 35 to 70 engaged in the Prospective Epidemiological Research Study in Iran (PERSIAN) cohort. Assessment of one year’s food intake via a validated 134-item semi-quantitative food frequency questionnaire (FFQ) facilitated the calculation of adherence to five diet quality indices: Dietary Approaches to Stop Hypertension (DASH), Mediterranean, Mediterranean-DASH Intervention for Neurodegenerative Delay (MIND), Dietary Inflammatory Index (DII), and Diet Quality Indices (DQI). While bivariate Pearson correlation and binary logistic regression aided in identifying the strongest correlation and predictor for MetS among the indices. Results This study showed a significant association between adhering to the DASH diet score, Mediterranean diet score, MIND diet score, DII score, and DQI score, and the odds of developing MetS (OR: 0.94, (95% CI: 0.93–0.95), OR: 0.85, (95% CI: 0.81–0.89), OR: 0.84, (95% CI: 0.80–0.89), OR: 1.22, (95%CI: 1.11–1.34), OR: 0.95, (95%CI 0.94–0.96) respectively). Therefore, with each unit increase in DASH diet score, Mediterranean diet score, MIND diet score, DII score, and DQI score, the odds of MetS was reduced by 5.4%, 14.5%, 15.6%, 22%, 5%, respectively. All the indices were correlated with the intake of most of the micronutrients, with the strongest correlations being observed in the DII. DASH diet score aligned with the most favourable MetS biomarker risk, while DII score primarily associated with MetS and could be considered as a predictor for MetS. Conclusion The present study’s findings reveal that between all these five diet quality indices, the DASH diet score correlates strongly with a favourable biomarker risk profile, while the DII score is predominantly linked to MetS.
Article
Full-text available
Fatty acids disorders may lead to insulin resistance, resulting in long-term oxidative stress and inflammatory processes, both mediated by adipose tissue. Either in normal condition or obesogenic status, adipose cells components play an important role in several physiological and metabolic conditions. It has been shown that bioactive compounds can influence the development of obesity and its pathological complications such as insulin resistance. In this study, we performed a network between bioactive compounds and adipose tissue vis-a-vis insulin resistance. We constructed a regulatory network of 62 adipocyte cell components that incorporates current evidence of cellular and molecular interactions involved in healthy and obesity states. The network incorporated information about inflammation pathways and inhibition of insulin signaling; insulin signaling and GLUT 4 translocation; triglycerides production; ATP production; M2 macrophages recruitment; adipogenesis and lipolysis as well as mitochondrial biogenesis. Our mathematical model showed a discernment between the impact of various bioactive substances on the transitions from health to obesity and vice versa. We found that anthocyanins, punicalagin, oleanolic acid, and NRG4 proved to be critical nodes in the transition from obesity to the healthy state, due to their switch-on potential to up-regulate the complex network resulting in a beneficial transition.
Article
Full-text available
The potential benefits of plant-based interventions in reducing the incidence and lessening the morbidity and mortality of COVID-19 have yet to be widely recognized. However, our groundbreaking research suggests that these interventions could be effective. In a recent publication, we utilized plant-based diets (PBDs) and supplements for 3470 high-risk elderly COVID-19 patients. The results were nothing short of remarkable, as we achieved a zero mortality rate, and none of our patients experienced worsening conditions or required hospitalization. This review article presents the mechanism of how PBD and supplement interventions can mitigate COVID-19 disease severity and avoid mortality. Our findings suggest that PBD and supplement interventions are not only effective but could revolutionize the management of coronavirus patients.
Article
Full-text available
Background: Extra virgin olive oil (EVOO), an essential element of the Mediterranean diet (MedDiet), has demonstrated considerable potential in improving mitochondrial health and protecting against chronic diseases. This narrative review aims to explore how the main phenolic compounds found in EVOO—hydroxytyrosol, oleuropein, and oleocanthal—contribute to mitochondrial health by reducing oxidative stress and inflammation. Methods: A search for scientific evidence was carried out between October 2024 and March 2025 in different bibliographic databases such as PubMed, Web of Science, Embase, SciSpace, and ResearchRabbit databases. The search strategy included combinations of terms such as “extra virgin olive oil”, “EVOO polyphenols”, “mitochondrial function”, “oxidative stress”, “inflammation”, “mitophagy”, and “chronic diseases”. Preclinical, clinical, and mechanistic studies were included, giving priority to peer-reviewed publications. Results: This narrative review shows how some bioactive components of EVOO activate cellular pathways, such as mTOR, AMPK and sirtuins, which promote mitochondrial biogenesis, improve the efficiency of the electron transport chain, and protect mitochondrial DNA integrity. Furthermore, EVOO improves mitochondrial membrane fluidity and integrity, ensuring its functionality and efficiency. On the other hand, nutrition literacy, an important component of health, is a critical determinant of people’s eating behaviors. Conclusions: Although recent scientific evidence supports the metabolic benefits of EVOO components on mitochondrial metabolism and function, further nutritional intervention studies with these components are recommended to confirm their clinical relevance as a dietary tool aimed at preventing and/or delaying age-related metabolic diseases.
Chapter
Metabolic syndrome (MetS) is referred to a cluster of dysregulated physiological and biochemical parameters such as dyslipidemia, hypertriglyceridemia, hyperglycemia, hypertension and obesity. Such abnormalities increase the predisposition to cardiovascular disease (CVD) and diabetes. In fact, the etiology of MetS could be determined by the interaction between genetic and environmental factors. While considered a disease in adults, risk factors for MetS have also been seen in children and adolescents. In addition, sex and ethnicity may also have an important role in the incidence of MetS that could not only influence the risk of CVD and diabetes, but may also impact the approaches undertaken for prevention and/or treatment of MetS. Accordingly, in this article we have described the impact of lipid metabolism dysregulation on MetS as well as some important considerations that could assist in the understanding of the risk and incidence/prevalence of MetS and their adverse outcomes.
Article
Full-text available
Academic medicine fosters research that moves from discovery to translation, at the same time as promoting education of the next generation of professionals. In the field of obesity, the supposed integration of knowledge, discovery and translation research to clinical care is being particularly hampered. The classification of obesity based on the body mass index does not account for several subtypes of obesity. The lack of a universally shared definition of “obesities” makes it impossible to establish the real burden of the different obesity phenotypes. The individual's genotype, adipotype, enterotype and microbiota interplays with macronutrient intake, appetite, metabolism and thermogenesis. Further investigations based on the concept of differently diagnosed “obesities” are required.
Article
Full-text available
The obesity epidemic shows no signs of abatement. Genetics and overnutrition together with a dramatic decline in physical activity are the alleged main causes for this pandemic. While they undoubtedly represent the main contributors to the obesity problem, they are not able to fully explain all cases and current trends. In this context, a body of knowledge related to exposure to as yet underappreciated obesogenic factors, which can be referred to as the "exposome", merits detailed analysis. Contrarily to the genome, the "exposome" is subject to a great dynamism and variability, which unfolds throughout the individual's lifetime. The development of precise ways of capturing the full exposure spectrum of a person is extraordinarily demanding. Data derived from epidemiological studies linking excess weight with elevated ambient temperatures, in utero, and intergenerational effects as well as epigenetics, microorganisms, microbiota, sleep curtailment, and endocrine disruptors, among others, suggests the possibility that they may work alone or synergistically as several alternative putative contributors to this global epidemic. This narrative review reports the available evidence on as yet underappreciated drivers of the obesity epidemic. Broadly based interventions are needed to better identify these drivers at the same time as stimulating reflection on the potential relevance of the "exposome" in the development and perpetuation of the obesity epidemic.
Article
Full-text available
Nonalcoholic fatty liver disease (NAFLD) is the most frequent liver disease worldwide. Gut microbiota can play a role in the pathogenesis of NAFLD since dysbiosis is associated with reduced bacterial diversity, altered Firmicutes/Bacteroidetes ratio, a relative abundance of alcohol‐producing bacteria, or other specific genera. Changes can promote disrupted intestinal barrier and hyperpermeability, filtration of bacterial products, activation of the immune system, and pro‐inflammatory changes in the intestine, in the liver, and at a systemic level. Microbiota‐derived molecules can contribute to the steatogenic effects. The link between gut dysbiosis and NAFLD, however, is confused by several factors which include age, BMI, comorbidities, dietary components, and lifestyle. The role of toxic chemicals in food and water requires further studies in both gut dysbiosis and NAFLD. We can anticipate that gut microbiota manipulation will represent a potential therapeutic tool to delay or reverse the progression of NAFLD, paving the way to primary prevention measures.
Article
Full-text available
Comprising over 1000 signatories representative of multiple stakeholders, including hepatologists, internists, diabetologists, endocrinologists, paediatricians, primary-care providers, nephrologists, cardiologists, pathologists, patient advocates, nurses, nutritionists, and pharmaceutical experts from over 134 countries, we—the undersigned—endorse both the name metabolic (dysfunction)-associated fatty liver disease (MAFLD) as an overarching term and its definition for fatty liver diseases associated with metabolic dysregulation. 1, 2, 3 We advocate for this change because it more accurately reflects the underlying pathogenesis of the disease than does the previously used term, non-alcoholic fatty liver disease (NAFLD). Furthermore, we believe that this designation will enhance our ability to advance the science of fatty liver disease and to improve patient care. 4, 5 This open letter represents the voices of individuals and multiple stakeholders across the global liver health community; it is not intended to devalue any other initiative, but to complement and inform them.
Article
Full-text available
Interest in plant-based food has grown in recent years due to their primary prevention potential. Za’atar, an ancient and popular Lebanese herbal mixture, might disclose relevant clinical interest, due to the well-known intrinsic properties of its individual components. Za’atar mixture contain Origanum syriacum (Lebanese thyme), Thymbra spicata (Wild thyme), Rhus coriaria (Sumac), and Sesamum indicum (Sesame). Here we explored the history, composition, general employment, and bio-active aspects of Za’atar through available in vitro, animal, and clinical trials evidence to depict its possible role as an innovative nutraceutical tool. The combined action of Za’atar constituents is able to generate comprehensive beneficial effects on several common pathogenic pathways underlying chronic cardio-metabolic diseases and cancer. However, main available evidence derives from animal and in vitro studies. Thus, further human studies are needed to fully characterize Za’atar as a preventive and curative tool.
Article
Full-text available
Gut microbiota encompasses a wide variety of commensal microorganisms consisting of trillions of bacteria, fungi, and viruses. This microbial population coexists in symbiosis with the host, and related metabolites have profound effects on human health. In this respect, gut microbiota plays a pivotal role in the regulation of metabolic, endocrine, and immune functions. Bacterial metabolites include the short chain fatty acids (SCFAs) acetate (C2), propionate (C3), and butyrate (C4), which are the most abundant SCFAs in the human body and the most abundant anions in the colon. SCFAs are made from fermentation of dietary fiber and resistant starch in the gut. They modulate several metabolic pathways and are involved in obesity, insulin resistance, and type 2 diabetes. Thus, diet might influence gut microbiota composition and activity, SCFAs production, and metabolic effects. In this narrative review, we discuss the relevant research focusing on the relationship between gut microbiota, SCFAs, and glucose metabolism.
Article
Full-text available
The largest surface of the human body exposed to the external environment is the gut. At this level, the intestinal barrier includes luminal microbes, the mucin layer, gastrointestinal motility and secretion, enterocytes, immune cells, gut vascular barrier, and liver barrier. A healthy intestinal barrier is characterized by the selective permeability of nutrients, metabolites, water, and bacterial products, and processes are governed by cellular, neural, immune, and hormonal factors. Disrupted gut permeability (leaky gut syndrome) can represent a predisposing or aggravating condition in obesity and the metabolically associated liver steatosis (nonalcoholic fatty liver disease, NAFLD). In what follows, we describe the morphological-functional features of the intestinal barrier, the role of major modifiers of the intestinal barrier, and discuss the recent evidence pointing to the key role of intestinal permeability in obesity/NAFLD.
Article
Full-text available
Some metabolic pathways involve two different cell components, for instance, cytosol and mitochondria, with metabolites traffic occurring from cytosol to mitochondria and vice versa, as seen in both glycolysis and gluconeogenesis. However, the knowledge on the role of mitochondrial transport within these two glucose metabolic pathways remains poorly understood, due to controversial information available in published literature. In what follows, we discuss achievements, knowledge gaps, and perspectives on the role of mitochondrial transport in glycolysis and gluconeogenesis. We firstly describe the experimental approaches for quick and easy investigation of mitochondrial transport, with respect to cell metabolic diversity. In addition, we depict the mitochondrial shuttles by which NADH formed in glycolysis is oxidized, the mitochondrial transport of phosphoenolpyruvate in the light of the occurrence of the mitochondrial pyruvate kinase, and the mitochondrial transport and metabolism of L-lactate due to the L-lactate translocators and to the mitochondrial L-lactate dehydrogenase located in the inner mitochondrial compartment.
Article
Introduction Loss of skeletal muscle mass and function (sarcopenia) is common in individuals with obesity due to metabolic changes associated with a sedentary lifestyle, adipose tissue derangements, comorbidities (acute and chronic diseases), and during the ageing process. Co-existence of excess adiposity and low muscle mass/function is referred to as sarcopenic obesity (SO), a condition increasingly recognized for its clinical and functional features that negatively influence important patient-centred outcomes. Effective prevention and treatment strategies for SO are urgently needed, but efforts are hampered by the lack of an universally established SO Definition and diagnostic criteria. Resulting inconsistencies in the literature also negatively affect the ability to define prevalence as well as clinical relevance of SO for negative health outcomes. Aims and methods The European Society for Clinical Nutrition and Metabolism (ESPEN) and the European Association for the Study of Obesity (EASO) launched an initiative to reach expert consensus on a Definition and diagnostic criteria for SO. The jointly appointed international expert panel proposes that SO is defined as the co-existence of excess adiposity and low muscle mass/function. The diagnosis of SO should be considered in at-risk individuals who screen positive for a co-occurring elevated body mass index or waist circumference, and markers of low skeletal muscle mass and function (risk factors, clinical symptoms, or validated questionnaires). Diagnostic procedures should initially include assessment of skeletal muscle function, followed by assessment of body composition where presence of excess adiposity and low skeletal muscle mass or related body compartments confirm the diagnosis of SO. Individuals with SO should be further stratified into Stage I in the absence of clinical complications, or Stage II if cases are associated with complications linked to altered body composition or skeletal muscle dysfunction. Conclusions ESPEN and EASO, as well as the expert international panel, advocate that the proposed SO Definition and diagnostic criteria be implemented into routine clinical practice. The panel also encourages prospective studies in addition to secondary analysis of existing datasets, to study the predictive value, treatment efficacy, and clinical impact of this SO definition.
Article
Sumac (Rhus coriaria L.) is a commonly used spice in the Mediterranean region and considered as healthy food ingredients. The beneficial value of sumac is well documented in folk medicine. Accumulating data explored the phytochemical, nutritional and therapeutic proprieties suggesting sumac as a potential functional food. Here, we discuss the general and scientific aspects of sumac. Sumac is rich in different polyphenolic compounds such as flavonoids, tannins, and phenolic acids. The potential therapeutic effects of sumac have been studied in various cellular and animal models, as well as in human. These reports suggest that Sumac has potential effect against oxidative stress, inflammation, obesity, hyperglycemia, hypercholesterolemia, and hyperlipidemia, which represent key pathogenic mechanisms contributing to cardio-metabolic, liver, and cancer diseases. Clinical studies using sumac or its major compounds, suggest that this herbal product may represent a useful therapeutic tool in the management of metabolic-related conditions such as liver-atherosclerosis complications.